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Thoracoscopy and talc poudrage compared with intercostal
drainage and talc slurry infusion to manage malignant
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Najib M Rahman,4 Robert F Miller5 and Nick A Maskell1*
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Background: There are around 40,000 new cases of malignant pleural effusion in the UK each year.
Insertion of talc slurry via a chest tube is the current standard treatment in the UK. However, some centres
prefer local anaesthetic thoracoscopy and talc poudrage. There is no consensus as to which approach is
most effective.
Objective: This trial tested the hypothesis that thoracoscopy and talc poudrage increases the proportion of
patients with successful pleurodesis at 3 months post procedure, compared with chest drain insertion and
talc slurry.
Design: This was a multicentre, open-label, randomised controlled trial with embedded economic
evaluation. Follow-up took place at 1, 3 and 6 months.
Setting: This trial was set in 17 NHS hospitals in the UK.
Participants: A total of 330 adults with a confirmed diagnosis of malignant pleural effusion needing
pleurodesis and fit to undergo thoracoscopy under local anaesthetic were included. Those adults needing
a tissue diagnosis or with evidence of lung entrapment were excluded.
Interventions: Allocation took place following minimisation with a random component, performed by a
web-based, centralised computer system. Participants in the control arm were treated with a bedside chest
drain insertion and 4 g of talc slurry. In the intervention arm, participants underwent local anaesthetic
thoracoscopy with 4 g of talc poudrage.
Main outcome measures: The primary outcome measure was pleurodesis failure at 90 days post
randomisation. Secondary outcome measures included mortality and patient-reported symptoms.
A cost–utility analysis was also performed.
Results: A total of 166 and 164 patients were allocated to poudrage and slurry, respectively. Participants
were well matched at baseline. For the primary outcome, no significant difference in pleurodesis failure
was observed between the treatment groups at 90 days, with rates of 36 out of 161 (22%) and 38 out
of 159 (24%) noted in the poudrage and slurry groups, respectively (odds ratio 0.91, 95% confidence
interval 0.54 to 1.55; p = 0.74). No differences (or trends towards difference) were noted in adverse
events or any of the secondary outcomes at any time point, including pleurodesis failure at 180 days
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[poudrage 46/161 (29%), slurry 44/159 (28%), odds ratio 1.05, 95% confidence interval 0.63 to 1.73;
p = 0.86], mean number of nights in hospital over 90 days [poudrage 12 nights (standard deviation 13 nights),
slurry 11 nights (standard deviation 10 nights); p = 0.35] and all-cause mortality at 180 days [poudrage
66/166 (40%), slurry 68/164 (42%); p = 0.70]. At £20,000 per quality-adjusted life-year gained, poudrage
would have a 0.36 probability of being cost-effective compared with slurry.
Limitations: Entry criteria specified that patients must be sufficiently fit to undergo thoracoscopy, which
may make the results less applicable to those patients presenting with a greater degree of frailty. Furthermore,
the trial was conducted on an open-label basis, which may have influenced the results of patient-reported
measures.
Conclusions: The TAPPS (evaluating the efficacy of Thoracoscopy And talc Poudrage versus Pleurodesis
using talc Slurry) trial has robustly demonstrated that there is no additional clinical effectiveness or
cost-effectiveness benefit in performing talc poudrage at thoracoscopy over bedside chest drain and talc
slurry for the management of malignant pleural effusion.
Trial registration: Current Controlled Trials ISRCTN47845793.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 26.
See the NIHR Journals Library website for further project information.
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Plain English summary
In patients with cancer, fluid can build up in the space between the chest wall and lung, causingbreathlessness. The fluid can be drained using a small tube inserted between the ribs under local
anaesthetic. However, it often recurs. To avoid this, doctors usually inject talc powder (mixed into a slurry)
back down the drainage tube to try to ‘stick’ the lung to the inside of the chest wall. If successful, this
prevents the fluid reforming. This procedure is called pleurodesis.
An alternative is to insert a camera into the chest under light sedation and local anaesthetic (a ‘thoracoscopy’)
and spray talc directly onto the inside of the chest wall (poudrage). This may be more effective, although this
has not been proven and it is a slightly more complex procedure.
Therefore, this trial was conducted to see if poudrage was more effective than slurry. A total of 330 patients
were recruited from 17 UK hospitals who had chest fluid due to cancer. They were divided evenly, with half
receiving standard drainage and slurry and the other half receiving a thoracoscopy and poudrage. They were
followed up for 6 months. We measured how many experienced a recurrence in fluid build-up 3 months
after treatment, as well as other impacts, including if there was any difference in the long-term costs.
No difference in clinical effectiveness was found between talc poudrage and talc slurry. Poudrage was
unlikely to be cost-effective.
In summary, the researchers conclude that slurry is likely to be the preferable method.
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Scientific summary
Background
Data suggest that there are around 40,000 new cases of malignant pleural effusion in the UK each year.
Malignant pleural effusion is usually a result of a metastatic process and patient survival is typically poor.
In general, average survival is quoted as being 4–6 months from diagnosis, although these data are drawn
from highly heterogeneous patient groups. In addition, there are a number of factors that appear to
influence survival, meaning that this figure may be less applicable to a number of patients. The underlying
cancer type, in particular, appears to exert a strong influence on outcome, with some series reporting that
those patients with mesothelioma (12 months) or breast cancer (> 2 years) survived longer.
For many patients, malignant pleural effusion can lead to debilitating symptoms, such as breathlessness or
chest pain. Therapeutic aspiration of pleural fluid can lead to rapid relief for patients and is readily performed
in the outpatient setting, although the volumes that can be removed in a single sitting are limited by the
potential adverse effects of rapid, high-volume lung re-expansion. For this reason, thoracocentesis is usually
considered to be a temporising measure rather than a definitive treatment, with recurrent aspirations
reserved for those patients with a very short life expectancy. Indwelling pleural catheters are an increasingly
used option, but this method of repeated drainage does not prevent fluid formation reliably, as recent data
suggest that this occurs in approximately 20% of cases when drained at a typical frequency.
The more traditional and established approach to malignant pleural effusion treatment, pleurodesis, entails
an attempt at preventing further fluid formation. This begins with emptying the chest of as much fluid as
possible, which is usually accomplished following insertion of an intercostal chest drain (at the bedside
under local anaesthetic) or during a thoracoscopic procedure (which may be performed under either light
sedation or general anaesthesia). Once the pleural cavity is evacuated, an irritant is applied to the pleural
linings with the intention of stimulating a local inflammatory response, resulting in fibrosis and adhesion
(effectively obliterating the pleural space and, hopefully, preventing any further effusion formation).
The primary perceived benefit of the pleurodesis approach is that a single intervention period can lead
to long-term fluid prevention; a number of small series have described success rates in excess of 80%.
Talc slurry via chest tube is the current standard treatment approach for pleurodesis in the UK. This method
has become ubiquitous as it is easily undertaken in the ward setting, with chest drain insertion possible at
the bedside and not typically requiring anything other than local anaesthesia. Talc poudrage requires the
capability to perform a thoracoscopy and for the patient to be able to tolerate such a procedure. Thoracoscopy
may be undertaken by surgeons under general anaesthetic (video-assisted thoracoscopic surgery) or, as is
increasingly the case in the UK, under light sedation (local anaesthetic thoracoscopy), the latter usually
being performed by respiratory physicians in a dedicated procedural environment.
There is currently no consensus as to which approach is best. To the best of our knowledge, the largest
study addressing the question of talc delivery for pleurodesis was performed by Dresler et al. and reported
in 2005 (Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup
study of talc poudrage vs talc slurry sclerosis for MPE. Chest 2005;127:909–15). After withdrawals and
exclusions, a total of 482 patients (slurry, n = 240; poudrage, n = 242) were included in the final analysis.
Based on intention to treat, no significant difference was found between the two arms at 30 days. Following
a per-protocol analysis, whereby patients with trapped lung were excluded, a significant difference (p = 0.045)
was found, favouring poudrage, although this effect disappeared when only patients who were alive at
30 days (slurry, n = 130; poudrage, n = 152) were included.
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Although undoubtedly important, the Dresler et al. 2005 study has not defined practice, as it was felt to
have encompassed several potentially important flaws and barriers to wider generalisability, particularly
in the UK. With the benefit of hindsight, these included a lack of detail regarding how randomisation,
concealment or powering of the trial occurred; the use of ungraded talc; the use of video-assisted thoracoscopic
surgery and general anaesthetic; the lack of an economic evaluation to inform broader utility and
cost-effectiveness; poor retention to follow-up; major differences in treatment arms, such as assessing
trapped lung using radiology in the slurry arm and intraoperatively in the other; no attempt at stratification
prior to randomisation; the use of post hoc analyses to draw and report study conclusions; and, perhaps
most importantly, a lack of what may be seen to be a clinically relevant or patient-centred definition of
pleurodesis success.
How best to deliver talc into the pleural space remains an unanswered but important question, with the
relatively poor-quality data described in the sections above failing to provide robust evidence to drive
standardised clinical practice. This is particularly the case in the UK, where the pleurodesis approach
offered will often be based on the individual preferences or beliefs of the treating clinician and the locally
available facilities.
Objectives
The evaluating the efficacy of Thoracoscopy And talc Poudrage versus Pleurodesis using talc Slurry (TAPPS)
trial aimed to be the first adequately powered, robustly designed trial comparing the efficacy of talc
poudrage (administered using local anaesthetic thoracoscopy) with the current standard treatment of a
chest drain followed by talc slurry, for the management of patients with MPE in the UK.
The primary research question was, for patients with a confirmed malignant pleural effusion and good
performance status, does thoracoscopy and talc poudrage increase the proportion of patients with
successful pleurodesis at 3 months post procedure, when compared with standard therapy with chest
drain insertion and talc slurry instillation?
Methods
Design
This was a pragmatic, multicentre, UK-based, open-label, randomised controlled trial. A within-trial
economic evaluation was conducted to assess the cost-effectiveness of both approaches. The TAPPS trial
was given initial ethics approval by the National Research Ethics Service Committee (reference number
12/NW/0467), sponsored by North Bristol NHS Trust and jointly managed by research teams based at the
University of Bristol and University of Oxford.
Inclusion criteria were as follows:
l a clinically confident diagnosis of MPE requiring pleurodesis, defined as –
¢ pleural effusion with histocytologically proven pleural malignancy, or
¢ pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear
alternative cause for fluid, or
¢ pleural effusion with typical features of malignancy with pleural involvement on cross-sectional
imaging without a clear alternative cause for fluid
l fit enough to undergo local anaesthetic thoracoscopy
l expected survival > 3 months
l written, informed consent to trial participation.
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Exclusion criteria were as follows:
l patients in whom thoracoscopy is the only reasonable approach to making a diagnosis and in whom
such a diagnosis would significantly influence further management
l aged < 18 years
l females who are pregnant or lactating
l evidence of extensive lung entrapment on chest radiography or computed tomography, or significant
fluid loculation on thoracic ultrasound, to a level that would normally be a contraindication to
attempted talc pleurodesis
l insufficient volume or position of pleural fluid on lateral decubitus thoracic ultrasound to safely perform
local anaesthetic thoracoscopy without further intervention being necessary
l previously documented adverse reaction to talc
l clear contraindication to thoracoscopy or chest tube insertion.
Sample size
Previous literature and local audit data suggested that patients with a World Health Organization
performance status score of 2 or better have approximate pleurodesis failure rates of 10% with a
thoracoscopy and 30% with standard chest tube and talc slurry pleurodesis.
Thus, to detect a 15% difference in pleurodesis failure at 3 months (10% thoracoscopy and poudrage
vs. 25% chest drain and talc slurry), with 90% power, a 5% significance level and 10% loss to follow-up,
a total of 325 patients was required.
The final recruitment target was rounded up to 330 patients, with 165 patients to be allocated equally to
each treatment arm.
No interim analyses were planned.
Consent and treatment allocation
All patients provided informed consent to trial entry. Patients were randomly assigned, in a 1 : 1 ratio,
to one of the trial treatments. Randomisation was performed centrally by the trial management team in
Oxford, using a computer-based system. Minimisation with a random element was utilised. The minimisation
factors were type of underlying malignant disease (mesothelioma, lung cancer, breast cancer, other) and
World Health Organization performance status (0–1, 2–3).
Because of the inherent and substantial differences between the two methods being tested, this trial could
not be performed ethically or safely in a blinded manner using dummy or sham procedures.
Trial treatments
Participants allocated to the control group underwent 12–14 French gauge chest drain insertion and were
then administered 4 g of sterile talc slurry. Drain removal and consideration for discharge occurred once
< 250 ml of fluid output was recorded in a 24-hour period.
Participants allocated to the intervention group underwent local anaesthetic thoracoscopy and talc poudrage
with 4 g of sterile talc slurry and insertion of a 16–24 French gauge chest drain at the end of the procedure.
After a minimum of 24 hours, drain removal and consideration for discharge occurred once < 250 ml of
fluid output was recorded in a 24-hour period.
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Follow-up period
Trial follow-up appointments took place at 1 month (day 28 ± 7 days), 3 months (day 84 ± 10 days) and
6 months (168 days ± 14 days) post randomisation.
Outcome measures
The primary end point was the number of patients who experienced pleurodesis failure up to 3 months
(90 days) post randomisation.
A patient was defined was experiencing pleurodesis failure if they underwent a therapeutic procedure on
the side ipsilateral to their trial intervention, or if this procedure was needed but not performed.
A range of secondary outcomes as also assessed, including patient-reported symptoms and quality of life,
pleurodesis failure rates at 30 and 180 days, and mortality.
Cost-effectiveness was assessed taking into account quality-adjusted life-years and resource use during the
initial procedure and over the trial period.
Results
Recruitment took place between August 2012 and October 2017, with 17 centres contributing participants.
The target of 330 patients was achieved, with 164 allocated to the control (slurry) arm and 166 to the
intervention (poudrage) arm. A total of 159 (97%) and 161 (97%) patients from the control and
intervention arms, respectively, were included in the primary outcome analysis. Fourteen (8.5%) and
15 (9.0%) patients from the control and intervention arms, respectively, withdrew during the 6-month
follow-up period. The treatment groups were well matched at baseline.
Primary outcome
For the primary outcome, no significant difference in pleurodesis failure was observed between the treatment
groups at 90 days, with rates of 36 out of 161 (22%) and 38 out of 159 (24%) noted in the poudrage and
slurry groups, respectively (odds ratio 0.91, 95% confidence interval 0.54 to 1.55; p = 0.74).
Secondary outcomes
No differences (or trends towards difference) were noted in any of the secondary outcomes at any time point,
including pleurodesis failure at 30 days [poudrage 16/161 (10%), slurry 22/159 (14%), odds ratio 0.69, 95%
confidence interval 0.34 to 1.37; p = 0.29]; pleurodesis failure at 180 days [poudrage 46/161 (29%), slurry
44/159 (28%), odds ratio 1.05, 95% confidence interval 0.63 to 1.73; p = 0.86]; mean number of nights in
hospital over 90 days [poudrage 12 nights (standard deviation 13 nights), slurry 11 nights (standard deviation
10 nights); p = 0.35]; all-cause mortality at 180 days [poudrage 66/166 (40%), slurry 68/164 (42%); p = 0.70];
thoracic pain (p = 0.69, p = 0.61, p = 0.85 and p = 0.78 at days 7, 30, 90 and 180, respectively); dyspnoea
(p = 0.51, p = 0.20, p = 0.58 and p = 0.41 at 7, 30, 90 and 180 days, respectively); or percentage radiographic
opacification (p = 0.66, p = 0.58, p = 0.45 and p = 0.79 at drain removal, at 30, 90 and 180 days, respectively).
Adverse events
There was no significant difference between the groups in the number of adverse events or serious adverse
events recorded at 7, 30 or 180 days. A total of 179 and 152 adverse events were recorded in the intervention
and control arms, respectively. The most commonly seen adverse events were worsening dyspnoea due to
disease-related fluid (poudrage, n = 23; slurry, n = 20), pneumothorax or bronchopleural fistula (poudrage,
n = 15; slurry, n = 18) and pneumonia or chest infection (poudrage, n = 25; slurry, n = 19).
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Cost-effectiveness
The mean total NHS and hospice care costs were £10,146 (95% confidence interval £9119 to £11,212) for
patients randomised to standard chest tube talc slurry pleurodesis and £10,687 (95% confidence interval
£9621 to £11,627) for patients randomised to thoracoscopy-delivered talc poudrage, a mean difference
of £541 (95% confidence interval difference –£953 to £1933). The mean quality-adjusted life-year gain
was 0.239 in the standard chest tube talc slurry pleurodesis group and 0.246 in the thoracoscopy-delivered
talc poudrage group, a mean difference of 0.007 quality-adjusted life-years (95% CI –0.019 to 0.034).
Therefore, the incremental cost per quality-adjusted life-year gained when poudrage was compared with
slurry was £77,286. At the conventional £20,000 per quality-adjusted life-year gained threshold,
thoracoscopy-delivered talc poudrage would have a 0.36 probability of being cost-effective.
Conclusions
The results of the TAPPS trial appear to be conclusive, in that there was no evidence of any difference
between the two treatment arms in the primary outcome measure: pleurodesis failure at 90 days post
randomisation. Indeed, no significant difference or trend towards difference was noted in any of the
secondary outcome measures, including pleurodesis failure up to the final follow-up visit at 180 days post
randomisation, mortality, time spent in hospital, radiological appearances or patient-reported outcomes.
Absolute values for pleurodesis failure were low (approximately 23% in both arms) at 90 days and this
was maintained for the duration of the trial (approximately 30% in both arms at 180 days). The health
economic analysis suggested that talc poudrage has a low probability (36%) of being cost-effective when
compared with talc slurry.
To the best of our knowledge, the TAPPS trial is the first randomised controlled trial to examine the
efficacy of talc poudrage delivered at LAT compared with traditional talc slurry. It addresses a clear and
important area of uncertainty in clinical practice and has been able to inform this definitively. The trial
processes, including randomisation and treatment allocations, were robustly designed, with the likelihood
of bias minimised as far as possible. The trial interventions were performed in a standardised fashion that
was reflective of current practice, meaning the results are likely to be generalisable to the wider population.
However, the trial entry criteria specified that patients be sufficiently fit to undergo local anaesthetic
thoracoscopy under light sedation, which may make the results less applicable to those patients presenting
with a greater degree of frailty. Furthermore, the trial was conducted on an open-label basis, which may
have influenced the results of patient-reported measures, such as pain or breathlessness. It is also probable
that those clinicians responsible for the recruitment and trial interventions were also required to assess
patients for pleurodesis failure, introducing the potential for bias (although this was considered and addressed
through blinded re-assessment).
Overall, the TAPPS trial has robustly demonstrated that there is no additional benefit in performing talc
poudrage at local anaesthetic thoracoscopy over bedside chest drain and talc slurry for the management of
malignant pleural effusion.
Trial registration
This trial is registered as ISRCTN47845793.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Scientific background
Pathophysiology of malignant pleural effusion
In a healthy individual, only a potential space exists between the two pleural layers (visceral and parietal).
A small volume of fluid is continuously produced and absorbed in equal measure. Absorption occurs via
a series of channels and pores, which are concentrated in the dependent portions of the parietal pleura.1
Malignancy can affect the pleura in a number of ways, all of which are likely to contribute to the formation
of malignant pleural effusion (MPE) through the disruption of the normal cycle of fluid production and
resorption. Direct tumour effects, typically as a result of primary tumour formation (mesothelioma) or
metastatic deposition, can lead to physical obstruction of drainage outlets. Indirect effects are thought to
arise as a result of cytokines, for example vascular endothelial growth factor, that either are secreted locally
or exert their influence via the bloodstream. Indirect effects are thought to arise as a result of cytokines, for
example vascular endothelial growth factor, which either are secreted locally or exert their influence via the
bloodstream, resulting in increased vascular permeability and/or pleural neoangiogenesis, both of which
predispose an individual to pleural fluid formation.2–4 The end result of these processes is a net increase in
the volume of fluid in the pleural space, resulting in an effusion that may, in certain cases, lead to physical
restriction and the development of associated symptoms.5 A particular hallmark of MPE is the tendency to
recur or to progress despite treatment or drainage.
Burden of malignant pleural effusion
Autopsy series have suggested that as many as 15% of cancers will lead to some form of macroscopically
evident pleural invasion.6 Despite this, it is probable that the incidence of MPE is under-reported, as
detection of malignant cells in fluid may be challenging7 and not all patients develop symptoms.
Data suggest that there are around 40,000 new cases of MPE in the UK each year,8 although these figures
may well prove to be conservative as improved detection techniques and life-prolonging treatments become
increasingly available. In addition, projections would estimate that there will be a year-on-year rise in the
number of newly diagnosed malignancies over the coming decade, driven largely by increases in population.9
Survival in malignant pleural effusion
Malignant pleural effusion is usually a result of a metastatic process; therefore, patient survival is typically
poor. In general, average survival is quoted as being 4–6 months from diagnosis, although these data
are drawn from highly heterogeneous patient groups.10–12 In addition, there are a number of factors
that appear to influence survival, meaning that this figure may be less applicable to a number of patients.
The underlying cancer type, in particular, appears to exert a strong influence on outcome, with some
series reporting that those patients with mesothelioma (12 months) or breast cancer (> 2 years) survived
longer.11,13
General approaches to malignant pleural effusion management
For many patients, MPE can lead to debilitating symptoms, such as breathlessness or chest pain.5 General
management of both of these symptoms, and others that may be associated with the underlying cancer,
form the cornerstone of all treatment strategies; however,14 in those patients with clinically significant
volumes of fluid, drainage is usually indicated in addition to broader symptomatic management. Therapeutic
aspiration of pleural fluid, whereby fluid is drawn off using simple apparatus, such as a needle and syringe,
can lead to rapid relief for many patients and is readily performed in the outpatient setting, although the
volumes that can be removed in a single sitting are limited by the potential adverse effects of rapid, high-volume
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lung re-expansion.15 For this reason, thoracocentesis is usually considered to be a temporising measure rather
than a definitive treatment, with recurrent aspirations reserved for those patients with a very short life
expectancy.5
Broadly, definitive MPE treatment can be divided into two approaches: (1) long-term fluid management
and (2) attempted fluid prevention. The fluid management approach accepts that fluid will recur and
prioritises treatments that will minimise patient time spent in hospital; in the UK, this typically involves
the insertion of an indwelling pleural catheter (IPC). IPCs are inserted as a day-case procedure under local
anaesthetic and are then drained regularly in the community by nursing teams, family members or the
patient themselves. Despite their potential benefits, an IPC cannot be relied on to stop fluid forming.
Recent data suggest that this occurs in approximately 20% of cases when drained at a typical frequency.16,17
In addition, for some, the inconvenience of a permanently sited tube, and the regular drainages it demands,
preclude IPC use.18 Furthermore, treatment with an IPC requires the infrastructure to insert and manage
the devices alongside the financial capability to support the regular use of the consumables they require,
factors that prevent their use in several countries.
The more traditional and established approach to MPE treatment is fluid prevention, or pleurodesis.
An attempt at pleurodesis begins with emptying the chest of as much fluid as possible, which is usually
accomplished following insertion of an intercostal chest drain (at the bedside under local anaesthetic)
or during a thoracoscopic procedure (which may be performed under either light sedation or general
anaesthesia). Once the pleural cavity is evacuated, an irritant is applied to the pleural linings with the
intention of stimulating a local inflammatory response, resulting in fibrosis and adhesion, effectively
obliterating the pleural space and, hopefully, preventing any further effusion formation. The primary
perceived benefit of the pleurodesis approach is that a single intervention period can lead to long-term
fluid prevention. A number of small series have described success rates in excess of 80%.5 However,
as with the alternative, a degree of compromise is necessary as pleurodesis approaches usually require
a period of inpatient treatment and may lead to more pain.19,20
In terms of patients’ symptoms, recent randomised controlled trial (RCT) evidence suggest that there is
parity between the pleurodesis approach and the fluid management approach with an IPC, with both
interventions improving symptoms to a clinically meaningful degree.20 Many centres, therefore, will choose
to offer patients the choice of how they wish their recurrent fluid to be managed: as an outpatient with an
IPC or as an inpatient with an attempt at pleurodesis.
Selecting a pleurodesis agent
In 2016, a Cochrane network meta-analysis21 examining the efficacy of various treatments for the management
of MPE was published. This study identified 62 RCTs for inclusion and used pleurodesis failure rate as its
primary outcome measure, but noted that there was an extremely high degree of heterogeneity in the design
and outcome reporting of the included studies, with a high risk of bias in many of them. With these limitations,
the conclusion was that talc is likely to be the most efficacious agent, overall, for inducing pleurodesis and,
in particular, it was suggested that talc given in the form of poudrage (sprayed directly onto the pleural as
a dry powder during a thoracoscopic procedure) was the best approach.21 It was recommended, however,
that a more effective comparison between this method and the alternative delivery method for talc – as a
slurry following drainage via bedside chest tube – be undertaken in the future.21
Talc slurry via chest tube is the current standard treatment approach for pleurodesis in the UK.5 This method
has become ubiquitous, as it is easily undertaken in the ward setting, with chest drain insertion possible at the
bedside and not typically requiring anything other than local anaesthesia. Talc poudrage requires the capability
to perform a thoracoscopy and for the patient to be able to tolerate such a procedure. Thoracoscopy may be
undertaken by surgeons under general anaesthetic [video-assisted thoracoscopic surgery (VATS)] or, as is
increasingly the case in the UK, under light sedation [local anaesthetic thoracoscopy (LAT)], the latter usually
being performed by respiratory physicians in a dedicated procedural environment.22
INTRODUCTION
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Current evidence comparing the use of talc poudrage with slurry
Previous randomised controlled trials
Three studies have directly compared talc slurry with talc poudrage in a randomised setting, totalling
599 patients, and describe conflicting results.23–25 All of these studies delivered poudrage using VATS under
general anaesthesia; to the best of our knowledge, there are no studies that have examined talc poudrage
delivered at LAT.
The earliest of these, Yim et al.,23 which included 57 patients from a single centre, concluded that there
was no significant difference between the two treatments and thus, because of the likelihood of increased
resources being required, recommended that talc slurry be the treatment of choice. This study, however,
as well as being significantly underpowered, chose to exclude all patients who were taking anticancer
therapies, which makes the study population less applicable to the typical patient presenting with MPE.23
In 2009, Terra et al.24 randomised 60 patients from a single centre, with the primary intention of examining
post-pleurodesis lung expansion. Although this was found to be better in the poudrage arm, this did not
translate into a meaningful clinical difference over longer-term follow-up. Once again, however, the wider
applicability of this study’s results may be questioned, as the population had an unusually low average age
(55 years) and the majority of patients were female, a trait also shared by the earlier Yim et al.23 study.
To the best of our knowledge, the largest study addressing the question of talc delivery for pleurodesis
was performed by Dresler et al.,25 reported in 2005. Participants were drawn from multiple North
American centres over a 5-year recruitment period and had to meet entry criteria that included being
suitable for general anaesthetic, having a performance status score of 0–2 and having an expected survival
of ≥ 2 months. Participants were excluded if they had received any previous intrapleural therapy, if they had
recently received systemic anticancer treatment or if they had bilateral effusions. Following randomisation,
patients would proceed on protocol only if there was evidence of adequate lung expansion. Patients in the
slurry arm had a chest tube (of unspecified size) inserted prior to 4–5 g of ungraded talc being instilled.
Those patients undergoing poudrage received the same dose of talc if the operating surgeon was satisfied
with a visual assessment of lung expansion, followed by drain insertion.25
The primary outcome for the Dresler et al. study25 was successful pleurodesis at 30 days. Secondary
outcomes included patient-reported breathlessness using a visual analogue scale (VAS), patient satisfaction,
complications, time to recurrence and quality of life using the Quality of Life Questionnaire – Cancer 30
(QLQ-C30). Interpretation of the primary end point was based on the reviewing surgeon’s interpretation
of the chest radiograph, although the authors state that a radiological opinion was also sought to
corroborate this.25
After withdrawals and exclusions, a total of 482 patients (slurry, n = 240; poudrage, n = 242) were
included in the final analysis. Based on intention to treat, no significant difference was found between the
two arms at 30 days. Following a per-protocol analysis, whereby trapped-lung patients were excluded, a
significant difference (p = 0.045) was found, favouring poudrage, although this effect disappeared when
only patients who were alive at 30 days (slurry, n = 130; poudrage, n = 152) were included. Of note, a high
number of complications were reported, including a perioperative mortality rate of 8.4% and a respiratory
failure rate of 8.1% in the poudrage arm. A post hoc analysis suggested that poudrage might be more
effective in those patients with MPE due to breast and lung malignancies.25
Although undoubtedly important, the Dresler et al. study25 has not defined practice as it was felt to have
encompassed several potentially important flaws and barriers to wider generalisability, particularly in
the UK. With the benefit of hindsight, these included a lack of detail regarding how randomisation,
concealment or powering of the trial occurred; the use of ungraded talc; the use of VATS and general
anaesthetic; the lack of an economic evaluation to inform broader utility and cost-effectiveness; poor
retention to follow-up; major differences in treatment arms, such as assessing trapped lung using radiology
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in the slurry arm and intraoperatively in the other; no attempt at stratification prior to randomisation;
the use of post hoc analyses to draw and report study conclusions; and, perhaps most importantly, a lack
of what may be seen to be a clinically relevant or patient-centred definition of pleurodesis success.25,26
Health economic analyses comparing slurry with poudrage
No published studies have directly measured the costs or cost-effectiveness of talc poudrage compared with
talc slurry for MPE; the limited number of studies in this area have tended to focus on the comparative costs
of IPC use following their introduction approximately 15 years ago.27–29 Two of these studies,27,29 however,
used theoretical modelling to compare treatments and included slurry and poudrage in their analyses.
The first,27 published as a 2011 conference abstract, is the only study to include LAT-delivered poudrage as
well as VATS poudrage, suggesting both that the latter was dramatically less cost-effective than the former
and that LAT poudrage and that talc slurry were very similar in terms of cost-effectiveness.27 The second
study, a further modelling exercise by Puri et al.,29 suggested that talc slurry is the optimal approach for
patients with a life expectancy of ≥ 1 year, when compared with either IPC or thoracoscopic poudrage
(the authors do not specify LAT or VATS).29
Local anaesthetic thoracoscopy in the UK
In the UK, over the last 20 years, there has been an expansion in the number of centres able to offer
physician-delivered LAT services.22 The wider availability of LAT services, and, by extension, of talc poudrage,
potentially opens up the possibility of treatment of MPE to a broader geographical range of patients than
VATS allows, as well as opening up the possibility of treatment to those patients who would perhaps be
unsuitable for general anaesthesia. It should be noted, however, that LAT is currently used primarily as a
diagnostic tool, with the overwhelming majority of procedures being performed in patients with a suspected,
but not yet established, diagnosis of pleural malignancy. In such a scenario, talc poudrage may still be
performed prior to conclusion of the procedure in order to reduce the likelihood of a patient needing a
further intervention for MPE later in their disease course.
Rationale for research
How best to deliver talc into the pleural space remains an unanswered but important question, with the
relatively poor-quality data described in Current evidence comparing the use of talc poudrage with slurry
failing to provide robust evidence to drive standardised clinical practice. This is particularly the case in the
UK, where the pleurodesis approach offered will often be based on the individual preferences or beliefs of
the treating clinician and the locally available facilities. Advocates for thoracoscopy and poudrage suggest
that this procedure, despite being more involved for patients and requiring greater health-care infrastructure,
offers a higher chance of long-term pleurodesis success (due to a more even powder distribution) and a
shorter initial stay in hospital (as all fluid is drained immediately prior to poudrage, rather than waiting for it
to drain gradually). Opponents to poudrage argue that there is a lack of evidence to support the view that
poudrage is better than slurry, and that the probable excess costs, lower availability and requirement for
greater baseline patient fitness make it the less preferable approach in routine care.
Primary research aim
The evaluating the efficacy of Thoracoscopy And talc Poudrage versus Pleurodesis using talc Slurry (TAPPS)
trial aimed to be the first adequately powered, robustly designed trial to compare the efficacy of talc
poudrage (administered using LAT) with the current standard treatment of a chest drain followed by talc
slurry, for the management of patients with MPE in the UK.
Research questions
The primary research question was, for patients with a confirmed MPE and good performance status,
does thoracoscopy and talc poudrage increase the proportion of patients with successful pleurodesis at
3 months post procedure when compared with the standard therapy of chest drain insertion and talc
slurry instillation?
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The secondary research questions were as follows:
l Does talc poudrage reduce the time to pleurodesis failure at 1 and 6 months post randomisation when
compared with talc slurry?
l Does talc poudrage at thoracoscopy improve chest radiographic appearances after initial drain removal
and at 1, 3 and 6 months post randomisation when compared with talc slurry?
l Does talc poudrage cause less breathlessness and thoracic pain for the first 7 days post randomisation
when compared with talc slurry?
l Does talc poudrage improve health-related quality of life (HRQoL) over the 6 months post
randomisation when compared with talc slurry?
l Does talc poudrage reduce health-care utilisation during the 6 months post randomisation when
compared with talc slurry instillation?
l Is talc poudrage cost-effective over 6 months when compared with talc slurry instillation?
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Chapter 2 Main trial design and methods
Trial design
The trial was a pragmatic, multicentre, UK-based, open-label RCT comparing two methods for delivering
talc for the management of MPE: (1) bedside chest drain and talc slurry and (2) LAT and talc poudrage.
The trial was not registered as a Clinical Trial of an Investigational Medicinal Product following discussion
with the Medicines and Healthcare products Regulatory Agency. A within-trial economic evaluation was
conducted to assess the cost-effectiveness of both approaches.
The trial protocol has been published and is available on an open-access basis.26 A general summary of the
trial processes can be found in Figure 1.
Table 1 describes the main differences between the TAPPS trial and the 2005 Dresler et al. study.25
MPE
Randomisation
Minimisation by type of malignancy and
WHO performance status
• 12–14 French chest drain
   insertion
• 4 g of intrapleural talc once
   lung expanded
• Drain out at least 24 hours
   post talc
Control arm
• LAT
• 4 g of talc poudrage at the end
   of the procedure
• 16–24 French drain insertion
• Drain out at least 24 hours
   post procedure
At 1, 3 and 6 months
Intervention arm
6-month follow-up
FIGURE 1 Trial summary flow chart. WHO, World Health Organization.
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Ethics approval
The TAPPS trial was given initial ethics approval by the National Research Ethics Service Committee
(North West – Preston) on 26 June 2012. The ethics approval number was 12/NW/0467.
All subsequent substantial amendments were reviewed and approved by the same committee.
Trial registration
The TAPPS trial was prospectively registered on the publicly accessible International Standard Randomised
Controlled Trial Number (ISRCTN) database prior to recruitment beginning (ISRCTN47845793).30 A
comprehensive lay summary was also prepared and made available on the Cancer Research UK website.31
Trial oversight and management
The trial was sponsored by North Bristol NHS Trust (local identification number 2843).
The TAPPS trial was managed jointly by research teams based at the University of Bristol and the University
of Oxford. The chief investigator, trial co-ordinator and lead trial nurse were based at the Academic
Respiratory Unit at the University of Bristol. The trial manager, trial database and data entry team were
based at Oxford Respiratory Trials Unit at the University of Oxford.
A Trial Management Group met and communicated regularly to ensure efficient day-to-day running of the
trial, protocol adherence, and that adverse events (AEs) and safeguarding issues were identified and acted
on swiftly.
The Trial Steering Committee (TSC) met at regular intervals (at least twice per year) and, in addition to the
chief investigator and trial statistician, consisted of independent physician and lay members in accordance
with the funder’s requirements.
An Independent Data and Safety Monitoring Committee met at regular intervals during the trial. After
reviewing the necessary data, they provided a recommendation to the chairperson of the TSC with regards
to trial continuation.
TABLE 1 Major differences between the TAPPS trial and Dresler et al. study25
Dresler et al.25 TAPPS trial
VATS only Medical LAT
Radiological outcome Clinical definition of pleurodesis
No health economics Full health economics
1-month primary end point 3-month primary end point
No stratification Minimisation
Disparity between pleurodesis methods Standardisation of therapy as best as possible
Ungraded talc Graded talc
Post hoc subgroup analysis A priori subgroup analysis
MAIN TRIAL DESIGN AND METHODS
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Participant selection and trial recruitment centres
Inclusion criteria
l Clinically confident diagnosis of MPE requiring pleurodesis, defined as:
¢ pleural effusion with histocytologically proven pleural malignancy, or
¢ pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear
alternative cause for fluid, or
¢ pleural effusion with typical features of malignancy with pleural involvement on cross-sectional
imaging without a clear alternative cause for fluid.
l Fit enough to undergo LAT.
l Expected survival of > 3 months.
l Written, informed consent to trial participation.
Exclusion criteria
l Patients in whom thoracoscopy is the only reasonable approach to making a diagnosis and in whom
such a diagnosis would significantly influence further management.
l Aged < 18 years.
l Female patients who were pregnant or lactating.
l Evidence of extensive lung entrapment on chest X-ray (CXR) or computed tomography, or significant
fluid loculation on ultrasound, to a level that would normally be a contraindication to attempted
talc pleurodesis.
l Insufficient volume or position of pleural fluid on lateral decubitus thoracic ultrasound to safely perform
LAT without further intervention being necessary.
l Previously documented adverse reaction to talc.
l Clear contraindication to thoracoscopy or chest tube insertion.
Recruitment centre selection
To be considered for participation in the TAPPS trial, all recruitment centres needed to:
l have a local principal investigator (PI) with an interest in pleural disease
l have an established medical thoracoscopy service
l expect to see at least 20 potentially eligible patients per year.
[The original ethics submission included eight sites based in England. Subsequently, an additional nine sites
(including centres in Wales and Scotland) were added. All site additions and removals were considered and
approved by the TSC.]
Changes to the original trial protocol
All changes to the trial protocol were made following consideration and approval by the TSC and, when
necessary, the Independent Data Monitoring Committee and ethics committee. Changes were typically
made in response to poorer-than-expected recruitment rates and these are summarised in Table 2.
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Sample size
The sample size calculation and all statistical analyses were performed using Stata® v15.1 (StataCorp LP,
College Station, TX, USA). Previous literature and local audit data suggested that patients with a
European Cooperative Oncology Group (ECOG) performance status score of 2 or better have approximate
pleurodesis failure rates of 10% with a thoracoscopy, and 30% with standard chest tube and talc slurry
pleurodesis.5,25
TABLE 2 Changes to the original trial protocol over the recruitment period
Study
amendment
number Details of significant alterations to protocol
Resulting protocol
version and date
1 Clarified various sections in the protocol
Altered the time window for a patient to consider trial entry
Updated flow charts
Clarified the use of suction and telephone follow-ups
2.0; 1 December 2012
2 No alterations as part of this amendment
3 Adjustments to the follow-up visit windows
Administrative details were updated throughout the protocol
3.0; 14 August 2013
4 Change of time allowance between the randomisation and the trial
procedure from 24 to 72 hours
Minor administration changes and clarifications to the protocol
4.0; 26 September 2013
5 No alterations as part of this amendment
6 Edited the safety reporting section of the protocol
Updated administrative details throughout the protocol
Added protocol appendix 6
5.0; 1 June 2014
7 Updated secondary end points following ratification of SAP version 1.0
Updated trial end date
Updated trial recruitment centre and PI details
Minor clarifications
6.0; 6 October 2014
8 Clarified that the first 7 days of VAS measurements were to be taken
post procedure, not post randomisation
Removed Leicester as recruiting site
7.0; 5 December 2014
9 Updated the PI at Wythenshawe Hospital
Added information regarding new sites
Updated the change in TSC membership information
8.0; 2 October 2015
10 Updated the PI at Addenbrooke’s Hospital
Removed Birmingham and Wrexham as active recruiting sites
Updated trial recruitment end date
9.0; 5 October 2016
SAP, statistical analysis plan.
MAIN TRIAL DESIGN AND METHODS
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Therefore, in order to detect a 15% difference in pleurodesis failure at 3 months (10% thoracoscopy and
poudrage vs. 25% chest drain and talc slurry), with 90% power, a 5% significance level and 10% loss to
follow-up, a total of 325 patients would be required.
The final recruitment target was rounded up to 330 patients, with 165 patients to be allocated equally to
each treatment arm.
No interim analyses were planned.
Participant recruitment
Patient identification and screening
Potential participants were identified locally from a range of sources, including:
l discussions at local multidisciplinary team meetings
l routine outpatient appointments
l inpatient ward reviews
l referrals from colleagues in oncology or acute medical settings.
Patients were assessed against the inclusion and exclusion criteria on a consecutive basis. A patient
information sheet was provided at the earliest opportunity, with each individual given enough time
(in their own opinion) to consider trial entry.
Each site maintained a local screening log. These were sent to the trial management team on a regular
basis and were used to identify potential challenges to recruitment and/or general patterns of behaviour
among patients and clinicians.
Informed consent
All participants provided written, informed consent to trial participation. It was suggested that consent
be taken as close as possible to the proposed date of randomisation, but these could occur up to 7 days
apart when necessary. A separate consent form was signed if the patient was willing to agree to sample
collection and storage for possible genetic testing in the future.
In addition to the above, all sites were expected to obtain separate consent for whichever procedure the
patient was allocated to, as per standard NHS practice.
Randomisation, concealment and blinding
Following consent, patients were randomly assigned, in a 1 : 1 ratio, to one of the treatment allocations
detailed below (see Treatment groups). Randomisation was performed centrally by the Trial Management
Team in Oxford. The team accessed an external computer-based system (Sealed Envelope™, London, UK)
on behalf of the randomising site, with local investigators required to confirm eligibility verbally over the
telephone before being notified of the allocation. Strict allocation concealment was maintained, with
treatment allocations becoming available only after the participant was enrolled and entered into the
randomisation system.
Minimisation with a random component of 80% was utilised. The minimisation factors were:
l type of underlying malignant disease (mesothelioma, lung cancer, breast cancer, other)
l World Health Organization (WHO)/ECOG performance status (0 or 1, 2 or 3).
It was intended that randomisation occur as close as possible to the intended procedure time.
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Because of the inherent and substantial differences between the two methods being tested, this trial could
not be performed ethically or safely in a blinded manner using dummy or sham procedures. The trial was
undertaken in an open-label manner, such that both the trial participant and the research team were
aware of the allocated intervention; however, the trial management team, including the TSC and Trial
Management Group, were blind to patient-level data throughout.
Treatment groups
A summary of the treatments given in each group can be found in Figures 2 and 3.
Seldinger chest drain insertion
CXR after 18–24 hours Consider suction
Lung expanded
and no significant
fluid?
≥  48 hours since
drain inserted?
Talc slurry Local physician decision regarding
ongoing management, including
checking drain patency
No
No
No
No
YesYes
Yes
Yes
Thoracic suction if available
(start at 5 cmH2O and increase to
20 cmH2O)
< 50% trapped
lung?
(estimated)
Tolerated?
24 hours minimum Off suction
Drain removal after minimum of
24 hours and once drainage is
< 250 ml/24 hours
Consider
drain-out
Consider
ongoing
suction
Post-removal CXR
FIGURE 2 Summary of treatments in control (slurry) arm.
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Control (slurry) group
Post randomisation, patients allocated to the control group underwent the following:
l Admission to an appropriate clinical area.
l Contemporaneous thoracic ultrasonography to guide drain placement.
l Pre-medication with analgesia as required.
l Instillation of local anaesthesia to proposed drain site.
l 12–14 French gauge chest drain insertion, using Seldinger technique, by an individual of adequate
training and experience.
l Assessment with CXR between 18 and 24 hours post drain insertion.
l Those patients without significant ongoing pleural opacification and/or unexpanded lung were given
4 g of sterile talc slurry (see Appendix 1 for full procedure). Those patients with ongoing opacification
or unexpanded lung could be placed onto thoracic suction at the discretion of the treating physician.
When on suction, patients underwent CXR every 24 hours with local teams instructed to consider talc
slurry instillation when there was evidence of at least 50% pleural apposition (by visual estimation).
l Thoracic suction (if available and tolerated) for a minimum of 24 hours post talc instillation.
l Drain removal, CXR and consideration for discharge once < 250 ml of fluid output was recorded in a
24-hour period.
Thoracoscopy + talc poudrage
Chest drain at end of procedure
Thoracic suction if available
(start at 5 cmH2O and increase to
20 cmH2O)
Tolerated?
Yes
Yes
No
No
24 hours minimum Off suction
CXR after 18–24 hours
Consider ongoing/increased
suction
Local physician decision regarding
ongoing management, including
checking drain patency
Drain out after minimum of
24 hours and once drainage is
< 250 ml/24 hours
Lung expanded
and no significant
fluid?
Post-removal CXR Consider drain out
FIGURE 3 Summary of treatments in intervention (poudrage) arm.
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Intervention (poudrage) group
Post randomisation, patients allocated to the intervention group underwent the following:
l Admission to an appropriate clinical area and listing for LAT at the earliest opportunity.
l LAT as per local standard practice (to include ultrasound guidance and light sedation), with complete
fluid drainage and diagnostic pleural sampling as required, performed by an individual of appropriate
training and experience.
l Talc poudrage with 4 g of sterile talc slurry (see Appendix 1 for full procedure).
l Insertion of a 16–24 French gauge chest drain at the end of the procedure.
l Thoracic suction (if available and tolerated) for a minimum of 24 hours immediately after the procedure.
l Assessment with CXR between 18 and 24 hours post procedure (with ongoing use of suction if deemed to
be necessary).
l After a minimum of 24 hours, drain removal, CXR and consideration for discharge once < 250 ml of
fluid output was recorded in a 24-hour period.
Standard care and co-enrolment during the trial period
During the trial, for all issues other than those pertaining to the drainage and management of the MPE,
treatment discretion lay with the primary clinician.
Normal clinical review during the trial period was to take place in the usual outpatient or inpatient
setting. The frequency of clinical review depended on patient choice, severity of symptoms and
clinical discretion.
Patients could withdraw from the trial at any time without their clinical care being affected.
An individual patient could be enrolled into the TAPPS trial only once. Once entered, patients were not to
be enrolled in any other trial that looked to directly influence the production of pleural fluid until the end
of their trial participation. Patients could still be considered for other studies, such as chemotherapy trials,
but discussion was to take place prior to enrolment to ensure compatibility between protocols.
Trial assessments and timings
Baseline assessment
Participants underwent a baseline assessment prior to their trial procedure. The standardised assessment
was to include:
l relevant current and past medical history
l symptom scores for pain and dyspnoea
l recent blood results
l quality-of-life assessments.
Intervention and inpatient period
Standardised data collection regarding the trial intervention was obtained, along with details of AEs in the
early post-procedure period.
Documentation of inpatient trial activity and outcomes was recorded in a standardised fashion at the time
of discharge.
MAIN TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Follow-up period and assessment of increasing breathlessness
Trial follow-up appointments took place at:
l 1 month (day 28 ± 7 days)
l 3 months (day 84 ± 10 days)
l 6 months (day 168 ± 14 days) post randomisation.
These appointments took place in the patient’s local trial hospital or an appropriate satellite centre,
and consisted of a standardised assessment and CXR.
All patients who were felt to have increasing breathlessness during the follow-up period were recommended
to undergo CXR. Any CXR that showed a degree of pleural opacification ipsilateral to the pleurodesis
attempt led to further imaging to confirm the presence of fluid. If fluid was confirmed and the CXR showed
pleural opacification to be one-third or greater than the volume of the hemithorax (by visual estimation),
the primary physician could undertake any further investigations or interventions as deemed appropriate.
In patients who had less than one-third of the hemithorax occupied by pleural fluid, the primary physician
was to discuss with another local physician, who was blinded to treatment arm, whether or not pleural
intervention was required. In the event of disagreement, or being unable to find a blinded physician, the chief
investigator could be contacted to make a casting decision (without being informed of the treatment arm).
Patient-reported outcomes
Trial participants were asked to complete two forms of patient-reported outcome measure:
1. VAS score for chest pain and dyspnoea
VAS scores were recorded at baseline and then daily for the first 7 days post procedure; following this,
scores were recorded on a weekly basis and at each follow-up visit
2. quality-of-life questionnaires
the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and Short Form questionnaire-36 items (SF-36)
HRQoL questionnaires were completed by all participants at baseline and at each subsequent trial visit.
Health economic diaries
Patients were provided with pre-printed diaries to keep with them for the duration of their trial involvement.
They were asked to record details of all personal contact with medical professionals (excluding trial visits) in
a basic standardised manner. These data were reviewed at each follow-up appointment.
An example of a standardised diary may be found in Report Supplementary Material 1.
Data acquisition and management
Data were collected in a variety of ways, depending on the type of information being acquired. All information
from trial visits was recorded locally on a series of paper case report forms, which were copied and sent to
the trial data team for screening, transcription and entry into the main database, which was run using the
OpenClinica 3.12.2 platform (OpenClinica LLC, Waltham, MA, USA).
The case report forms were supplemented by VAS collection booklets (see Report Supplementary Material 2)
and health-care utilisation diaries, as described above, which patients completed at home and brought to
each trial visit.
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Outcome measures
Primary outcome
The primary end point was the number of patients who experienced pleurodesis failure up to 3 months
(90 days) post randomisation.
A patient was defined as experiencing pleurodesis failure if they underwent any of the following
procedures on the side ipsilateral to their trial intervention:
l therapeutic pleural aspiration of ≥ 100 ml
l insertion of an intercostal drain for fluid drainage
l insertion of an IPC
l medical or surgical thoracoscopy.
A patient was also deemed to have failed pleurodesis if their primary physician decided that they required
one of the above pleural interventions, but the intervention was not performed (e.g. in the event of death
or patient choice against procedure).
The 90-day end point was chosen with a view to providing useful clinical information to patients with
a presumed average life expectancy of 4–6 months, as was expected in the target trial population.
Although failure rate at 30 days had previously been used in a major study,25 this was felt, in general,
to be too short an interval. Conversely, we believed a primary outcome measured later, at 180 days
post randomisation, would increase the risk of insufficient data being available due to mortality from
underlying malignancy. Nonetheless, pleurodesis failure at both 30 and 180 days were included as
secondary outcomes.
Secondary outcomes
In addition to the above, the following secondary outcomes were assessed:
l the number of patients with pleurodesis failure up to 30 days post randomisation
l the number of patients with pleurodesis failure up to 180 days post randomisation
l percentage radiographic (CXR) pleural opacification at the 1-, 3- and 6-month post-randomisation
follow-up visits, and after initial drain removal
l self-reported HRQoL at the 1-, 3- and 6-month follow-up post-randomisation visits, as measured using
the SF-36 and EQ-5D-5L questionnaires
l self-reported thoracic pain and breathlessness at 7 days post procedure, and at 30, 90 and 180 days
post randomisation, measured using VAS scores
l all-cause mortality up to 180 days post randomisation
l time to pleurodesis failure, censored at 180 days post randomisation
l number of nights spent as a hospital inpatient up to 90 days post randomisation, including length
of initial stay.
The original trial protocol also included the following secondary outcome: requirement for further pleural
procedures up to 180 days post randomisation, based on an independent, blinded assessment. However,
following approval from the TSC, this outcome was removed prior to the trial database being locked.
The reason and justification for this change can be found in Table 3.
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Exploratory outcomes
The following outcomes were added during the trial on a purely exploratory basis:
l categorical version of percentage radiographic (CXR) pleural opacification at the 1-, 3- and 6-month
post-randomisation follow-up visits and after initial drain removal, with categories –
¢ no fluid visible
¢ 1–24% opacification due to fluid (small effusion)
¢ 25–49% due opacification due to fluid (moderate effusion)
¢ ≥ 50% opacification due to fluid (large effusion)
l degree of visible lung entrapment on CXR at 6 months post randomisation, with categories –
¢ no lung entrapment
¢ minor lung entrapment (1–24% unexpanded lung)
¢ moderate lung entrapment (25–49% unexpanded lung)
¢ severe lung entrapment (≥ 50% unexpanded lung).
These additions occurred without the Trial Management Team being aware of any results, following
completion of recruitment but before database lock.
TABLE 3 Summary of changes to the original statistical analysis plan
Change Notes/justification
Changed method of analysis for pleurodesis failure from
competing risk time-to-event model to logistic regression
model
To match what was specified in the protocol
Removed secondary outcome ‘requirement for further
pleural procedures up to 180 days post randomisation,
based on an independent, blinded assessment’
Blinded assessment and corroboration of the need for
pleural intervention were already required for any case,
which is likely to be contentious. Without clinical contact,
the information on which specified assessment would be
made was felt to be insufficient to determine whether or
not a further pleural procedure would have been necessary;
thus, the clinical relevance of the outcome was felt to be
doubtful. It is probable that this assessment would have
relied primarily on the patient’s CXR appearance, which is
being addressed as another secondary outcome
Restricted subgroup analyses to only the primary outcome
Updated Stata command for analysing CXR pleural
opacification, EQ-5D-5L, SF-36, thoracic pain and
breathlessness, from ‘xtmixed’to ‘mixed’
The command ‘mixed’ replaced ‘xtmixed’ in more recent
versions of Stata
Removed sensitivity analysis for primary outcome based on
measuring pleurodesis failure from date of procedure rather
than date of randomisation
Removed the subgroup analysis for use of NSAIDs
at baseline
This question has now been addressed more
comprehensively in the TIME1 trial
Removed the subgroup analysis for previous radiotherapy
at baseline
This was not felt likely to be of clinical relevance
Added additional exploratory outcomes
Specified that AEs and SAEs would be summarised and
analysed within 7 days of randomisation (in addition to
within 30 and 180 days)
To better reflect the immediate post-procedure and
inpatient period
NSAID, non-steroidal anti-inflammatory drug; SAE, serious adverse event; TIME1, the first Therapeutic Interventions in
Malignant Effusion.
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Adverse events
Adverse events and serious adverse events (SAEs) were defined, documented and assessed in line with
standard practice. All SAEs were independently reviewed with regards to safety (by the sponsor) as close
as possible to the time of occurrence. On completion of the trial, all AEs and SAEs were independently
reviewed and coded.
Statistical analysis
The primary analysis for each outcome was performed using intention-to-treat principles, meaning that all
patients on whom an outcome was available were included in the analysis, and were analysed according to
the treatment group to which they were randomised.32 Patients with missing outcome data were excluded
from the analysis. All tests were two sided and were considered statistically significant at the 5% level.
All analyses were adjusted for the minimisation variables, with these included as covariates in the
regression model for each outcome33,34 [type of underlying malignant disease (mesothelioma, lung cancer,
breast cancer, other) and WHO performance status (0–1 or 2–3)].
Primary outcome
The primary outcome (pleurodesis failure at 90 days post randomisation) was analysed using a logistic
regression model. As specified above, the model was adjusted for the minimisation variables and excluded
patients with missing outcome data.
Subgroup analyses
Subgroup analyses were prespecified and performed for the primary outcome. Results from subgroup
analyses were viewed as hypothesis-generating only. The following analyses were performed:
l patients receiving anticancer therapy at baseline compared with those patients not receiving anticancer
therapy at baseline
l WHO performance status (0 vs. 1 vs. 2 vs. 3)
l patients on steroids at baseline compared with those patients not on steroids at baseline
l previous attempt at pleurodesis in the previous month compared with no attempt in the previous month
l patients with primary malignancy of breast cancer compared with mesothelioma, lung cancer and
other cancer.
Secondary outcomes
l Pleurodesis failure at 30 and 180 days was analysed in the same manner as the primary outcome,
using a logistic regression model adjusted for the minimisation factors.
l Percentage chest radiographic opacification was analysed using a mixed-effects linear regression model.
Fixed effects were treatment group, time point, a treatment-by-time interaction and the minimisation
factors. An unstructured correlation matrix was used to model the correlation between outcomes at
different time points.
l HRQoL, using the EQ-5D-5L and SF-36 questionnaires, was analysed using the same approach as
percentage chest radiographic opacification above (i.e. using mixed-effects linear regression model,
adjusted for treatment, time point and a treatment-by-time interaction). In addition to the minimisation
factors, the analyses also adjusted for baseline questionnaire scores.
l Chest pain and dyspnoea were analysed using the same approach as above and adjusted for the
baseline VAS scores.
l All-cause mortality was analysed using a logistic regression model.
l The time to pleurodesis failure was analysed using a Fine–Gray competing risk time-to-event model,
with mortality as the competing risk.35
l The number of days spent in hospital was analysed using a negative binomial regression model,
with the number of days of follow-up included in the model as an offset.
MAIN TRIAL DESIGN AND METHODS
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Exploratory outcomes
l The exploratory outcome of the categorical version of percentage radiographic pleural opacification was
analysed using a mixed-effects ordinal logistic regression model, with a random intercept for patient.
The model was adjusted for the minimisation variables.
l The exploratory outcome of the degree of visible lung entrapment was analysed using an ordinal logistic
regression model, adjusted for the minimisation variables.
Bias reduction
Because of the open-label nature of this trial, the potential for introducing bias into data collection and
analysis was considered inherently greater than if the trial was performed in a fully blind fashion, especially
given that the local trial research teams were typically also responsible for the clinical management of
participants. Therefore, in order to minimise the possibility of bias in the primary outcome, the decision to
undertake further pleural intervention in patients who develop breathlessness and have a small-volume
recurrent effusion was discussed with a blinded assessor. This blinded assessor could be a clinician at the
local recruiting site or, if necessary, the chief investigator.
Changes to original statistical analysis plan
All changes to the original statistical analysis plan were agreed by the TSC and occurred prior to the trial
database being locked.
A summary of the changes can be found in Table 3.
Sensitivity analyses
Sensitivity to missing data for the primary outcome was assessed under a range of missing-not-at-random
scenarios. For each scenario, a treatment effect and 95% confidence interval (CI) were calculated and
compared with results from the main analysis of the primary outcome to see if conclusions were affected
by different assumptions regarding the missing data.
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Chapter 3 Health economic analysis design
and methods
Objective
The objective of the health economic element to the trial was to determine whether or not a LAT-delivered
talc poudrage was more cost-effective than standard chest tube talc slurry pleurodesis in patients with MPE.
Analysis perspective and aims
The health economic analysis took place from a UK NHS and Personal Social Services perspective. HRQoL data
and health-care resource use and cost data were used to examine the following:
l the cost of performing both trial interventions
l the follow-up health-care resource use and costs for trial participants in both groups
l HRQoL, through calculation of utility values using the EQ-5D-5L and Short Form questionnaire-6
Dimensions (SF-6D)
l the incremental cost-effectiveness ratio (ICER) when thoracoscopy-delivered talc poudrage was
compared with standard chest tube talc slurry pleurodesis.
Data collection
Quality of life
Generic HRQoL was measured using the SF-36 and the EQ-5D-5L.36,37
In the EQ-5D-5L, patients are asked to think about their health on the day that they are completing the
questionnaire and to report any problems (none, slight, moderate, severe and unable/extreme) on five
attributes (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Patients are then
required to rate their health using a 100-point VAS (0 = worst health you can imagine to 100 = best health
you can imagine). The EuroQoL-5 Dimensions (EQ-5D) is a standardised measure of health, providing a
simple generic measure of health for clinical and economic appraisal.
In the SF-36, patients are asked to think about their health in terms of eight health concepts: (1) physical
functioning (10 items); (2) social functioning (two items); (3) role limitations due to physical problems
(four items); (4) role limitations due to emotional problems (three items); (5) mental health (five items);
(6) energy/vitality (four items); (7) pain (two items); and (8) general health perceptions (five items). It also
includes questions providing an indication of perceived change in health.
Both quality-of-life questionnaires were completed at randomisation and then at 1, 3 and 6 months post
randomisation.
Resource use
As part of the NHS and Personal Social Services perspective adopted, we included the following health and
hospice care resource-use categories over the 6-month follow-up:
l Resource use involved with trial procedures, including time in surgical theatre; health-care staff involved;
surgical disposables (e.g. surgical gowns, gloves, drapes, syringes, sutures and drains); medication
(including talc) and sedation; capital equipment (e.g. video stack use, warmer, thoracoscopes and light
cables); and investigations (e.g. thoracic ultrasound and CXRs).
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l Initial hospitalisation after trial intervention. For each hospitalisation, information was recorded on the
date of admission and discharge, and the dates of transfers between different specialty wards.
l Follow-up hospital resource use, including outpatient visits; visits to accident and emergency (A&E);
ambulance use; outpatient visits; and day cases and length of stay in hospital, including stays in an
intensive treatment unit.
l Community care use, including visits to a general practitioner (at surgery, home or through the
telephone); nurse (at surgery or at home); physiotherapist; occupational therapist; psychologist;
and counsellor.
l Palliative and hospice care, including contacts with a palliative care nurse and number of nights spent
as an inpatient in a hospice.
Resource use involved with trial procedures was obtained by observing a number of trial interventions at
the trial site at the Churchill Hospital (NHS Oxford University Hospitals NHS Foundation Trust). Details
about the initial hospitalisation were obtained through a staff questionnaire to be completed once the
patient had been discharged.
All other follow-up resource use was collected using patient questionnaires administered at 1, 3 and
6 months. As an aide memoire, patients were also provided with a resource-use log designed for them
to fill in every time they had a contact with the health-care system. In the questionnaires, we did not
distinguish whether the contacts with the health-care service were through the NHS, Personal Social Services
or private providers, and we assumed that all contacts were financed by the NHS or Personal Social Services,
in a bid to keep the questionnaires as simple as possible. For missing values (e.g. patients who died halfway
through follow-up), clinical staff completed some of the questions, including ambulance and A&E use,
outpatient visits and hospitalisations, through review of patients hospital records.
Unit costs
Unit costs for the initial hospital admission were derived from NHS reference costs for the year 2013/14,38
as they contained information on costs by medical specialty. Unit costs for consultations with general
practitioners and nurses were obtained from the Personal Social Services Research Unit’s Unit Costs of
Health and Social Care publications for 2015 and 2017.39,40
For all other contacts, unit costs were derived from the NHS National Schedule of Reference Costs 2016 to
2017.41 For outpatient visits, we used the weighted average of all consultant-led, non-admitted, face-to-face
attendances, either first or follow-up. For physiotherapists, occupational therapists and psychologists, we
also used the weighted average of all consultant-led, non-admission, face-to-face attendances for each of
these three therapists. In the absence of specific unit costs for counsellors, we assumed that these would be
the same as for a psychologist. For visits to A&E, we used the weighted average of all emergency medicine
contacts, excluding dental care and patient dead on arrival. For ambulance transport to A&E, the unit cost
of a call to the emergency services was included as well as that for ambulance transport.
Using the reasons for hospitalisation reported by patients in the resource-use questionnaires, we obtained
diagnosis and procedure codes. These were then translated into a Healthcare Resource Group (HRG) using
the HRG4+ 2016/17 Reference Costs Grouper (NHS Digital). Each HRG was then linked to a series of
elective, non-elective and day-case reference costs obtained from the 2016/17 schedule of reference costs.
All costs were updated to 2016/17 using the Hospital and Community Health Service index.40
Statistical analysis
Quality of life
At each follow-up, responses to each of the five questions in the EQ-5D-5L were presented. As recommended
by the National Institute for Health and Care Excellence (NICE),42 EQ-5D-5L responses were converted into
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utilities using the validated mapping function to derive utility values for the EQ-5D-5L from the existing
EuroQol-5 Dimensions, three-level version.43
For each follow-up, the score for each of the eight dimensions of the SF-36 were coded, summed and
transformed on to a scale from 0 (worst possible health state) to 100 (best possible health state). We also
estimated the two standardised summary scores of the SF-36: the physical component score and the mental
health component score.37 SF-36 responses were then converted into utilities using the SF-6D algorithm
developed by Brazier et al.44
The SF-36 items scores, utility values (both for the EQ-5D-5L and SF-6D) and EQ-5D VAS scores at each
follow-up are presented as mean [standard deviation (SD)]. Mean differences across the two treatment
groups are presented alongside 95% CIs, with statistical significance assessed using two-sided t-tests.
Quality-adjusted life-years
Survival was estimated using the Kaplan–Meier survival function 6 months post randomisation. A quality-
adjusted survival curve was generated by plotting, against time, the product of the mean utility of patients
living at time t and the probability of surviving to time t, in order to create three periods (i.e. randomisation
to 1-month follow-up, 1- to 3-month follow-up and 3- to 6-month follow-up). The area under this quality-
adjusted survival curve then gave the mean quality-adjusted survival in each treatment group. Utility
was assumed to change linearly between each follow-up, rather than changing at the mid-point between
follow-ups or being maintained from one follow-up to another.
For each treatment group, results are reported as quality-adjusted life-years (QALYs) with 95% CIs
calculated non-parametrically from 1000 bootstrap differences. Mean QALY differences between the two
patient groups were also presented with 95% CIs, estimated using the 1000 bootstrap differences. Results
are presented for the whole patient sample (i.e. when patients who withdrew from the analysis were
treated as censored and missing utility estimates were assumed to be the same as the mean for that
treatment group).
Resource use
Initial length of stay and all follow-up contacts, at each follow-up visit, with health or social care services
were reported as means (SD), with differences between the two groups assessed using a Student’s t-test.
Six-month resource-use totals were evaluated using an available-case analysis (i.e. for each treatment
group, average resource use was summed over the three follow-up periods). Results are then presented as
means together with 95% CIs, generated through 1000 bootstrap estimates. Mean differences were also
estimated, as well as the 95% CI of the difference using bootstrapping.
Costs of providing the trial procedures
Time spent by participants in theatre was costed using Scottish information on theatre services,45 excluding
costs for medical, nursing and other staff, drugs and other supplies (as this information was collected
directly by the trial). For participants undergoing standard chest tube talc slurry pleurodesis, we also
excluded central sterile supply department costs, as all equipment used was disposable. Capital equipment
(including video stack, thoracoscopes, light cable, pre-heater and tube inserts) costs used to perform the
thoracoscopy-delivered talc poudrage were obtained directly from the manufacturer. To obtain an
equivalent annual cost for all capital equipment, we depreciated the acquisition costs over their assumed
5-year lifetime, using an annual rate of 3.5%. To obtain per-minute costs, we assumed that this equipment
would be used for 4 hours per week over 50 weeks per year.
Costs of staff time
This included the consultant physician, specialist registrar, nurse and health-care assistant and was valued
using average salaries for that position.40 Unit costs of disposables was valued using prices obtained from
the NHS Supply Chain.46 Costs of medications and sedation drugs were obtained from the British National
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Formulary.47 Finally, costs of investigations undertaken as part of the intervention, including CXRs and
thoracic ultrasonography, were obtained from NHS reference costs.41
Total costs
Costs of the initial hospitalisation, and costs incurred between each follow-up visits, are presented as
means (SD), with differences between the two patient groups assessed using a Student’s t-test. Six-month
total costs were evaluated using an available-case analysis (i.e. for each treatment group, average total
costs were summed over the three follow-up periods), as well as initial hospitalisation and intervention
costs. Results are then presented as means with 95% CIs, generated through 1000 bootstrap estimates.
Mean differences were also estimated, as well as the 95% CI of the difference, using bootstrapping.
Cost-effectiveness
In order to evaluate if thoracoscopy-delivered talc poudrage was cost-effective when compared with
standard chest tube talc slurry pleurodesis, we carried out an incremental analysis, with the mean cost
difference between thoracoscopy-delivered talc poudrage and standard chest tube talc slurry pleurodesis
divided by the mean QALY difference to give the ICER. As per NICE recommendations,48 we judged an
intervention to be cost-effective if the ICER was ≤ £20,000 per QALY gained.
However, given that average life expectancy in patients enrolled in the TAPPS trial was < 1 year, it could
be argued that NICE’s end-of-life criteria for assessing cost-effectiveness might apply.49 As a result, in
sensitivity analyses, we evaluated the impact of increasing the cost-effectiveness threshold to £50,000 per
QALY gained.50
We used the non-parametric percentile method for calculating the CI around the ICER, using 1000 bootstrap
estimates of the mean cost and QALY differences.51 Results of the 1000 bootstrap estimates are also
presented in the cost-effectiveness plane. We used the cost-effectiveness acceptability curve to show the
probability that thoracoscopy-delivered talc poudrage is cost-effective at 6 months for the £20,000 and
£50,000 per QALY NICE thresholds, and also for different values of the NHS’s willingness to pay for an
additional QALY.52
To account for the possibility that LATs performed during the trial were of a longer duration than those LATs
that might be performed in clinical practice, we undertook a one-way sensitivity analysis to examine the
impact on the results of shortening the duration of thoracoscopy-delivered talc poudrage by 10 minutes.
Multiple imputation
As the analysis of the TAPPS trial data were undertaken on an intention-to-treat basis, multiple imputation
was used to impute missing cost and utility values.53–55 As per recommended best practice, imputation was
implemented separately by randomised treatment allocation.56 Costs were imputed at the most disaggregated
level at which the model would converge. As a result, we imputed values for general practice consultation
costs (at practice, home and telephone); hospitalisation costs (outpatient visits, A&E and ambulance, inpatient
stays and day cases); hospice and nursing costs (hospice stays, and hospice and other nurse visits); and other
health-care costs (physiotherapy, occupational therapy, counselling and psychologist visits).
Rather than imputing missing responses for each of the five domains in the EQ-5D-5L, we imputed
the overall EQ-5D-5L utility.57 The imputation of costs and utility was conducted using predictive mean
matching (i.e. imputes data from similar patients with complete data) to account for the skewed nature
HEALTH ECONOMIC ANALYSIS DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
of both cost and utility data. Imputation was conducted using age, sex, baseline utility levels and the trial
minimisation criteria (i.e. type of underlying malignant disease and WHO/ECOG performance status).
We generated 60 replacement values for each missing case, generating 60 imputed data sets.
Using the Stata ‘mi estimate command’, we obtained mean estimates of cost and utility and SD.
Differences across patients groups were obtained using ordinary least squares regression using the
‘mi estimate: reg’ command.
DOI: 10.3310/hta24260 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 26
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Bhatnagar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25

Chapter 4 Main trial results
Recruitment
Recruitment took place between August 2012 and October 2017, with 17 centres contributing participants.
Table 4 shows the distribution of recruitment by site.
Flow of participants in the trial
The target of 330 participants was achieved, with 164 participants allocated to the control (slurry) arm and
166 participants to the intervention (poudrage) arm. A total of 159 (97.0%) and 161 (97%) participants,
respectively, were included in the primary outcome analysis. Fourteen (8.5%) and 15 (9.0%) participants,
respectively, withdrew during the 6-month follow-up period.
A comprehensive overview of participant flow, including screening activity, is given in the Consolidated
Standards of Reporting Trials (CONSORT) flow diagram in Figure 4.
TABLE 4 Recruitment by site
Site Approval date Final recruitment total
Taunton 2 November 2012 54
South Manchester 15 March 2013 38
Oxford 9 November 2012 30
Nottingham 22 October 2012 27
Bristol 26 September 2012 26
Glasgow 5 September 2014 26
King’s Mill 23 October 2012 24
Cambridge 3 April 2013 22
Glan Clwyd 24 February 2015 19
Preston 9 January 2013 13
Doncaster 19 March 2014 13
St Thomas’ (London) 18 December 2013 10
North Tees 26 June 2014 9
Medway 30 October 2012 7
Milton Keynes 24 October 2014 7
Aintree 2 September 2014 4
Birmingham 20 October 2014 1
Total – 330
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Screened
(n = 1121)
Not approached
(n = 538)
Not enrolled
(n = 253)
Approached
(n = 583)
Enrolled
(n = 330)
Allocated to poudrage
(n = 166)
Received poudragea
(n = 161)
Included in primary analysisb
(n = 161)
Included in primary analysisb
(n = 159)
Allocated to slurry
(n = 164)
Received slurrya
(n = 144)
Reasons included
• IPC preferred (n = 95)
• survival of < 3 months (n = 92)
• other physician decision (n = 43)
• not fit for LAT (n = 34)
• further tissue needed (n = 30)
• unable to consent (n = 28)
• treated before enrolment (n = 28)
• trapped lung (n = 22)
• LAT contraindicated (n = 21)
• patient preferred slurry (n = 16)
• administrative (n = 13)
• other patient decision (n = 13)
• assorted other (n = 12)
• patient did not want to participate
   in research (n = 10)
• patient decision unspecified (n = 44)
• no information available (n = 37)
Reasons included
• patient decision unspecified (n = 79)
• survival of < 3 months (n = 23)
• patient did not want to participate
   in research (n = 16)
• preferred slurry (n = 15)
• other patient decision (n = 14)
• preferred poudrage (n = 13)
• further tissue needed (n = 11)
• not fit for LAT (n = 11)
• administrative (n = 9)
• LAT contraindicated (n = 8)
• IPC preferred (n = 7)
• other physician decision (n = 6)
• treated before enrolment (n = 5)
• assorted other (n = 5)
• unable to consent (n = 3)
• trapped lung (n = 1)
FIGURE 4 The trial CONSORT flow diagram. a, Reasons for not receiving allocated treatment: poudrage arm –
thoracoscopy not attempted (n= 2), procedure abandoned before talc (n= 2), talc not given because of rapid lung
expansion on coughing (n= 1); slurry arm – chest drain not attempted (n= 2), talc not given (n = 18) because of
lung expansion (n= 6), lung entrapment (n= 5), excessive fluid production (n= 1), drain dislodgement (n= 1), early
drain removal (n= 1), loculated pleural space (n= 1), missing data (n= 3); and b, patients were not included in the
primary outcome analysis if there were no data available regarding pleurodesis failure at 90 days post randomisation.
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Baseline characteristics
In general, both treatment groups were well matched at baseline. A higher proportion of participants in
the control group (33/164, 20%) were noted to be receiving chemotherapy at enrolment than in the
intervention group (15/166, 9%). The mean age at enrolment was 68 years in both groups. The majority
of participants (79% control, 78% intervention) were of ECOG performance status 1 or 2. The commonest
underlying cancer types were lung and breast cancer.
Table 5 describes the full set of baseline characteristics.
TABLE 5 Baseline characteristics
Characteristic
Treatment arm, summary
measure Treatment arm, number with missing data
Thoracoscopy
and poudrage
Chest drain
and slurry
Thoracoscopy and
poudrage (N= 166)
Chest drain and
slurry (N= 164)
Age (years), mean (SD) 68 (11) 68 (12) 0 (0) 0 (0)
Chest pain (VAS), mean (SD) 17 (23) 18 (25) 1 (1) 1 (1)
Breathlessness (VAS), mean (SD) 53 (29) 53 (33) 1 (1) 1 (1)
Percentage radiographic (CXR)
pleural opacification, mean (SD)
54 (20) 47 (20) 129 (78) 127 (77)
Blood measurements
Hb, mean (SD) 131 (20) 129 (19) 3 (2) 3 (2)
Sodium, mean (SD) 136 (10) 137 (4.0) 3 (2) 2 (1)
INR, median (IQR) 1.0 (1.0–1.1) 1.0 (1.0–1.1) 38 (23) 38 (23)
WCC, mean (SD) 9.8 (14) 9.5 (9.4) 2 (1) 3 (2)
Potassium, mean (SD) 5.0 (5.1) 4.5 (2.2) 6 (4) 7 (4)
APTT, mean (SD) 27 (14) 28 (12) 30 (18) 22 (13)
Platelets, mean (SD) 342 (119) 334 (124) 3 (2) 3 (2)
Urea, mean (SD) 5.8 (3.0) 6.6 (7.6) 5 (3) 9 (5)
CRP, mean (SD) 46 (60) 46 (53) 35 (21) 26 (16)
Creatinine, mean (SD) 74 (29) 75 (28) 4 (2) 2 (1)
General categorical variables, n (%)
Female 96 (58) 85 (52) 0 (0) 0 (0)
Smoking status 1 (1) 0 (0)
Current smoker 13 (8) 12 (7)
Ex-smoker 104 (63) 98 (60)
Never smoker 48 (29) 54 (33)
WHO score 1 (1) 0 (0)
0 17 (10) 18 (11)
1 82 (50) 81 (49)
2 46 (28) 49 (30)
3 20 (12) 16 (10)
Effusion on right-hand side 91 (55) 91 (55) 0 (0) 0 (0)
continued
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TABLE 5 Baseline characteristics (continued )
Characteristic
Treatment arm, summary
measure Treatment arm, number with missing data
Thoracoscopy
and poudrage
Chest drain
and slurry
Thoracoscopy and
poudrage (N= 166)
Chest drain and
slurry (N= 164)
Pleural intervention in previous
3 months
117 (70) 121 (74) 0 (0) 0 (0)
Pleurodesis attempt in previous
month
2 (1) 3 (2) 0 (0) 0 (0)
Length of symptoms (weeks) 0 (0) 0 (0)
< 1 5 (3) 6 (4)
1–3 40 (24) 35 (21)
> 3 121 (73) 123 (75)
Percentage radiographic (CXR)
pleural opacification
129 (78) 127 (77)
1–24 3 (8) 4 (11)
25–49 15 (41) 18 (49)
≥ 50 19 (51) 15 (41)
Underlying cancer type 0 (0) 0 (0)
Lung 59 (36) 54 (33)
Mesothelioma 15 (9) 19 (12)
Breast 50 (30) 49 (30)
Ovarian 6 (4) 7 (4)
Lymphoma 3 (2) 2 (1)
Upper GI 4 (2) 4 (2)
Lower GI 6 (4) 9 (5)
Renal 5 (3) 11 (7)
Other 15 (9) 5 (3)
Unknown 3 (2) 4 (2)
Analgesia
Oral steroids 22 (13) 24 (15) 0 (0) 1 (1)
NSAIDs 21 (13) 29 (18) 0 (0) 1 (1)
Analgesic 118 (71) 107 (66) 0 (0) 1 (1)
Cancer treatment
One or more anticancer
treatment
44 (27) 55 (34) 0 (0) 1 (1)
Radiotherapy 48 (29) 40 (25) 0 (0) 1 (1)
Cancer-modulating
hormone therapy
27 (16) 17 (10) 0 (0) 1 (1)
Anticancer monoclonal
antibodies
5 (3) 6 (4) 0 (0) 1 (1)
Chemotherapy 15 (9) 33 (20) 0 (0) 2 (1)
Other anticancer therapy 2 (1) 6 (4) 0 (0) 1 (1)
Anticoagulant therapy 29 (17) 35 (21) 0 (0) 1 (1)
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Adherence to interventions
A total of 144 out of 164 (88%) of participants received their treatment as intended in the control arm,
compared with 161 out of 166 (97%) of participants in the intervention arm. Of those patients in the
control arm, 18 out of 20 participants did not receive talc after chest drain insertion.
A summary of treatment adherence (and the reasons for non-adherence) can be found in Tables 6 and 7.
TABLE 5 Baseline characteristics (continued )
Characteristic
Treatment arm, summary
measure Treatment arm, number with missing data
Thoracoscopy
and poudrage
Chest drain
and slurry
Thoracoscopy and
poudrage (N= 166)
Chest drain and
slurry (N= 164)
Comorbidities
COPD/asthma 20 (12) 18 (11) 0 (0) 0 (0)
Interstitial lung disease 1 (1) 1 (1) 0 (0) 1 (1)
Bronchiectasis 1 (1) 2 (1) 0 (0) 0 (0)
Pulmonary hypertension 0 (0) 0 (0) 0 (0) 0 (0)
Other respiratory disease 4 (2) 5 (3) 0 (0) 0 (0)
Ischaemic heart disease 11 (7) 13 (8) 1 (1) 0 (0)
Atrial fibrillation 14 (8) 10 (6) 0 (0) 0 (0)
Heart failure 1 (1) 2 (1) 0 (0) 0 (0)
Other cardiac disease 27 (16) 19 (12) 0 (0) 0 (0)
Minimisation factors, n (%)
Underlying malignancy 0 (0) 0 (0)
Lung 57 (34) 57 (35)
Breast 50 (30) 48 (29)
Mesothelioma 16 (10) 17 (10)
Other 43 (26) 42 (26)
Grouped WHO score 0 (0) 0 (0)
0–1 99 (60) 99 (60)
2–3 67 (40) 65 (40)
APTT, activated partial thromboplastin time; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein;
GI, gastrointestinal; Hb, haemoglobin; INR, international normalised ratio; IQR, interquartile range; NSAID, non-steroidal
anti-inflammatory drug; WCC, white cell count.
TABLE 6 Summary of treatment adherence
Treatment adherence
Treatment arm, n (%)
Thoracoscopy and poudrage (N= 166) Chest drain and slurry (N= 164)
Treatment given as intended
No 5 (3) 20 (12)
Yes 161 (97) 144 (88)
Reason treatment not given as intended
Procedure not attempted 2 (1) 2 (1)
Procedure abandoned 2 (1) 0 (0)
Talc not given 1 (1) 18 (11)
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Details of interventions
The median [interquartile range (IQR)] duration of the control procedure was 30 (IQR 20–40) minutes. The
median duration of the intervention procedure was 49 (IQR 40–60) minutes. A total of 110 of 164 (67%) of
LAT procedures, compared with 62 of 163 (38%) control procedures, were performed by consultant-grade
doctors. A total of 111 of 153 (73%) and 120 of 161 (75%) of participants in the control and intervention
groups, respectively, had thoracic suction applied during their post-procedure period. A comprehensive
summary of intervention details can be found in Table 8.
The frequency of complications during both trial procedures was low. Of note, 12 out of 161 (7%) and
8 out of 161 (5%) participants in the intervention arm were documented as experiencing new hypotension
and a drop in transcutaneous oxygen saturations, respectively, after talc was given. No participants in the
control arm experienced either of these events either before or after talc was given. A comprehensive
summary of recorded procedural complications can be found in Table 9.
TABLE 7 Reasons (and numbers of) patients not given talc
Reason
Treatment arm (n)
Thoracoscopy and poudrage (N= 1) Chest drain and slurry (N= 18)
Poor lung expansion/trapped lung 0 9
Excessive pleural production 0 1
Othera 1 5
Missing 0 3
a Intervention arm: rapid lung reinflation on coughing (n = 1). Control arm: drain fell out (n = 1), clinical decision (n = 1),
patient deterioration (n = 1), drain removed (n = 1), pleural space complex/septated (n = 1).
TABLE 8 Details of allocated treatments
Characteristic
Treatment arm, summary
measure
Treatment arm, number of
participants without data
Thoracoscopy
and poudrage
Chest drain
and slurry
Thoracoscopy and
poudrage (N= 166)
Chest drain and
slurry (N= 164)
Duration of procedure (minutes), mean (SD) 51 (22) 32 (13) 15 (9) 26 (16)
Grade of operator, n (%) 2 (1) 1 (1)
CT1/CT2 0 (0) 10 (6)
Consultant 110 (67) 62 (38)
F1/F2 0 (0) 4 (2)
Other 0 (0) 9 (6)
Registrar 54 (33) 78 (48)
Total fluid (ml) drained as an inpatient, mean (SD) 3442 (1831) 2890 (2094) 11 (7) 10 (6)
Evidence of lung entrapment: 18–24 hours, n (%) 60 (36) 55 (34)
None 85 (80) 90 (83)
Mild 8 (8) 8 (7)
Moderate 8 (8) 7 (6)
Severe 5 (5) 4 (4)
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TABLE 8 Details of allocated treatments (continued )
Characteristic
Treatment arm, summary
measure
Treatment arm, number of
participants without data
Thoracoscopy
and poudrage
Chest drain
and slurry
Thoracoscopy and
poudrage (N= 166)
Chest drain and
slurry (N= 164)
Evidence of lung entrapment: discharge, n (%) 61 (37) 66 (40)
None 92 (88) 90 (92)
Mild 1 (1) 4 (4)
Moderate 4 (4) 1 (1)
Severe 8 (8) 3 (3)
Thoracic suction used, n (%) 120 (75) 111 (73) 5 (3) 11 (7)
Time drain removed, n (%) 13 (8) 7 (4)
On time 113 (74) 126 (80)
Early 12 (8) 11 (7)
Late 28 (18) 20 (13)
CT1, core medical trainee 1; CT2, core medical trainee 2; F1, Foundation year 1 doctor; F2, Foundation year 2 doctor.
TABLE 9 Summary of treatment complications
Complication
Treatment summary measure, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
During procedure 164 with data available 162 with data available
Bleeding 1 (1) 0 (0)
Significant cough 4 (2) 2 (1)
Syncope 2 (1) 1 (1)
Significant pain 0 (0) 3 (2)
Pleural space not entered 1 (1) 0 (0)
New hypoxia 2 (1) 0 (0)
Dysrhythmia 0 (0) 0 (0)
New hypotension 4 (2) 0 (0)
Other 3 (2) 1 (1)
After talc 161 with data available 144 with data available
Nausea 3 (2) 2 (1)
Respiratory distress 0 (0) 0 (0)
GCS score drop of > 2 points 0 (0) 0 (0)
Uncontrolled pain 7 (4) 1 (1)
New hypotension 12 (7) 0 (0)
Saturation drop 8 (5) 0 (0)
Allergic reaction 0 (0) 0 (0)
New confusion 0 (0) 0 (0)
Bleeding 0 (0) 0 (0)
Other 6 (4) 5 (3)
GCS, Glasgow Coma Scale.
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Primary outcome
Treatment efficacy at 90 days
A total of 97% of participants in both arms (159/164 control, 161/166 intervention) were included in
the primary outcome analysis. No significant difference in pleurodesis failure was observed between the
treatment groups at 90 days, with failure rates of 22% (36/161) and 24% (38/159) noted in the poudrage
and slurry groups, respectively [adjusted odds ratio (OR) 0.91, 95% CI 0.54 to 1.55; p = 0.74].
Sensitivity analysis
Sensitivity analyses for the primary outcome evaluated how sensitive results were to departures from the
missing-at-random assumption described above by conducting various missing-not-at-random analyses;
these analyses made different assumptions about the event rates for participants with missing data in the
control and intervention arms. Results are shown in Figure 5, which shows the treatment effect as a
difference in proportions. Results were very robust to alternative assumptions regarding the missing data.
Subgroup analyses
We found moderate evidence of a subgroup effect between participants taking oral steroids at baseline and
those participants not taking oral steroids (p-value for interaction 0.04). In the subgroup on oral steroids,
there was a lower rate of pleurodesis failure (6/24, 25%) in the control group than in the intervention group
(10/20, 50%) (adjusted OR 3.13, 95% CI 0.84 to 11.61). Conversely, in the subgroup not on oral steroids,
there was a slightly higher rate of pleurodesis failure in the control arm (32/134, 24%) than in the
intervention arm (26/141, 19%) (adjusted OR 0.71, 95% CI 0.39 to 1.29).
No significant interaction effects were found in the use of anticancer therapy at baseline, previous
attempts at pleurodesis, baseline performance score or type of underlying malignancy. All prespecified
subgroup analysis results can be found in Table 10.
All treatment effects are adjusted for the minimisation factors.
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FIGURE 5 Sensitivity analysis for the primary outcome.
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Secondary outcomes
Secondary outcome results are summarised in Table 11. No statistically significant differences were seen in
any outcome at any time point. Figure 6 demonstrates the Kaplan–Meier plot for pleurodesis across all
time points, with the reasons for pleurodesis failure given in Table 12. Results relating to quality-of-life
secondary outcomes can be found in Chapter 5.
TABLE 10 Prespecified subgroup analyses for the primary outcome
Subgroup
Treatment arm, summary measure, n/N (%)
Adjusted OR
(95% CI)
p-value for interaction
with treatment
Thoracoscopy and
poudrage
Chest drain and
slurry
Anticancer therapy at baseline
No 25/118 (21) 29/105 (28) 0.65
(0.35 to 1.23)
Yes 11/43 (26) 9/53 (17) 1.96
(0.71 to 5.45)
0.08
Attempt at pleurodesis in previous month
No 34/159 (21) 38/156 (24) 0.85
(0.50 to 1.45)
Yes 0/2 (0) 0/3 (0) Not estimated Not estimated
On steroids at baseline
No 26/141 (18) 32/134 (24) 0.71
(0.39 to 1.29)
Yes 10/20 (50) 6/24 (25) 3.13
(0.84 to 11.61)
0.04
WHO score
0 4/15 (27) 0/16 (0) Not estimated
1 18/82 (22) 23/80 (29) 0.68
(0.33 to 1.42)
2 12/44 (27) 11/48 (23) 1.37
(0.52 to 3.58)
3 2/20 (10) 4/15 (27) 0.29
(0.04 to 1.91)
0.29
Primary malignancy
Lung 10/55 (18) 16/56 (29) 0.55
(0.23 to 1.36)
Breast 13/49 (27) 11/46 (24) 1.15
(0.46 to 2.92)
Mesothelioma 7/16 (44) 6/16 (38) 1.31
(0.32 to 5.38)
Other 6/41 (15) 5/41 (12) 1.23
(0.34 to 4.39)
0.60
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TABLE 11 Summary of secondary outcomes
Outcome
Treatment arm, summary
measure (%)
Adjusted
treatment
effect estimate
(95% CI) p-value
Treatment arm, number of
patients with data available (%)
Thoracoscopy
and poudrage
(N= 166)
Chest drain
and slurry
(N= 164)
Thoracoscopy
and poudrage
(N= 166)
Chest drain
and slurry
(N= 164)
Pleurodesis failure
(30 days), n (%)
16 (10) 22 (14) 0.69 (0.34 to 1.37) 0.29 161 (97) 159 (97)
Pleurodesis failure
(180 days), n (%)
46 (29) 44 (28) 1.05 (0.63 to 1.73) 0.86 161 (97) 159 (97)
Time to pleurodesis
failure,a median (IQR)
NR (91–NR) NR (80–NR) 1.01 (0.67 to 1.52) 0.98 161 (97) 159 (97)
All-cause mortality
(180 days), n (%)
66 (40) 68 (42) 0.91 (0.58 to 1.44) 0.70 165 (99) 163 (99)
Nights as hospital
inpatient within
90 days, mean (SD)
12 (13) 11 (10) 1.11 (0.89 to 1.37) 0.35 165 (99) 162 (99)
Thoracic pain (VAS),b
mean (SD) change
from baseline
142 (86) 146 (89)
7 days 1.0 (25) 2.3 (28) –1.2 (–6.9 to 4.6) 0.69
30 days –1.5 (25) –5.6 (26) 1.2 (–3.5 to 6.0) 0.61
90 days –2.5 (23) –6.9 (24) 0.5 (–4.8 to 5.8) 0.85
180 days –2.0 (23) –6.2 (23) 0.8 (–4.6 to 6.2) 0.78
Breathlessness (VAS),b
mean (SD) change
from baseline
142 (86) 146 (89)
7 days –31 (32) –29 (35) –2.0 (–8.0 to 4.0) 0.51
30 days –28 (32) –23 (39) –4.4 (–11.1 to 2.3) 0.20
90 days –25 (35) –29 (36) 2.1 (–5.4 to 9.6) 0.58
180 days –30 (33) –29 (43) –3.8 (–12.7 to 5.2) 0.41
Percentage
radiographic pleural
opacification,
mean (SD)
125 (75) 115 (70)
Drain removal 16 (12) 17 (15) –0.8 (–4.5 to 2.9) 0.66
1 month 25 (19) 26 (18) –1.5 (–6.7 to 3.7) 0.58
3 months 20 (19) 21 (19) –2.5 (–8.9 to 3.9) 0.45
6 months 17 (14) 16 (13) –0.8 (–6.7 to 5.1) 0.79
NR, not reached.
a 49/159 (31%) of participants in the control group and 42/161 (26%) participants in the intervention group died before
experiencing pleurodesis failure, and 44 (28%) and 46 (29%) participants in the control and intervention groups,
respectively, experienced pleurodesis failure within 180 days of randomisation. The adjusted hazard ratio from a post
hoc Cox model that does not incorporate mortality as a competed risk was 1.01 (0.67 to 1.52).
b Analysis is of outcome adjusted for baseline measure.
Notes
All treatment effects are difference in means, except for pleurodesis failure and all-cause mortality (ORs); time to pleurodesis
(hazard ratio) and nights in hospital (rate ratio). All treatment effects are adjusted for the minimisation factors.
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FIGURE 6 Kaplan–Meier plot for pleurodesis failure.
TABLE 12 Reasons for pleurodesis failure (all time points)
Mode of pleurodesis failure
Treatment arm (n)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
Pleurodesis failure (90 days) (primary outcome)
Therapeutic aspiration of ≥ 100ml 12 9
Insertion of intercostal drain for fluid drainage 7 7
Insertion of IPC 14 17
Medical/surgical thoracoscopy 1 0
Procedure required, but not done 2 5
Pleurodesis failure (30 days)
Therapeutic aspiration of ≥ 100ml 6 7
Insertion of intercostal drain for fluid drainage 3 4
Insertion of IPC 6 7
Medical/surgical thoracoscopy 0 0
Procedure required, but not done 1 4
Pleurodesis failure (180 days)
Therapeutic aspiration of ≥ 100ml 16 12
Insertion of intercostal drain for fluid drainage 8 8
Insertion of IPC 17 19
Medical/surgical thoracoscopy 2 0
Procedure required, but not done 3 5
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Missing data summaries for relevant secondary outcomes can be found in Tables 13–15.
Figure 7 demonstrates the recorded time to mortality in both groups and Table 10 shows the reasons for
pleurodesis failure at both 30 and 90 days.
TABLE 13 Summary of missing data for thoracic pain VAS
Time point
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
7 days 58 (35) 66 (40)
30 days 43 (26) 40 (24)
90 days 75 (45) 71 (43)
180 days 98 (59) 95 (58)
At least one measurement available 142 (86) 146 (89)
TABLE 14 Summary of missing data for dyspnoea VAS
Time point
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
7 days 60 (36) 65 (40)
30 days 43 (26) 40 (24)
90 days 75 (45) 71 (43)
180 days 98 (59) 96 (59)
At least one measurement available 142 (86) 146 (89)
TABLE 15 Summary of missing data for percentage radiographic pleural opacificationa
Time point
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
Drain removal 61 (37) 66 (40)
1 month 77 (46) 88 (54)
3 months 101 (61) 117 (71)
6 months 131 (79) 127 (77)
At least one measurement available 125 (75) 115 (70)
a These summaries also represent the number of missing data for the exploratory outcome of categorical version of
percentage radiographic pleural opacification.
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Exploratory outcomes
The results for the exploratory outcomes can be found in Tables 16–18. Analysis of lung entrapment was
not performed as the outcome was the same across all participants in both treatment arms.
Post hoc summaries and analyses
Treatment delay and initial inpatient stay
Delay from randomisation to allocated treatment is summarised in Table 19. A total of 18 out of 164
(11.0%) participants in the control arm waited for ≥ 1 day, whereas 38 out of 164 (23.2%) participants in
the intervention group waited for ≥ 1 day.
There was no difference between the groups in the mean length of initial hospital stay from randomisation
to discharge [control 5.7 (SD 5.6) days vs. intervention 5.8 (SD 9.7) days, rate ratio 1.00, 95% CI 0.85 to
1.19; p = 0.99].
Talc administration
A total of 18 out of 164 (11.0%) participants in the control arm did not receive talc slurry following
drain insertion. One out of 166 (0.6%) participants in the intervention arm did not receive talc despite
undergoing LAT. The reasons for not receiving talc, as well as the clinical outcomes of these participants,
are summarised in Tables 7 and 20.
Thoracic suction
Limited data were available regarding time spent on thoracic suction (control 84/164, 51.2% vs. intervention
90/166, 54.2%). Those participants in the control arm spent a median of 26.3 (IQR 21.0–46.7) hours on
suction compared with a median of 45.7 (IQR 36.0–71.0) hours in the intervention group.
Early symptom scores
Figures 8 and 9 show the between-group differences in dyspnoea and chest pain over the first 7 days post
randomisation.
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FIGURE 7 Time to mortality. Reproduced with permission from JAMA. 2020. 323:60–69. Copyright©2020 American
Medical Association. All rights reserved.
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TABLE 17 Categorical version of percentage radiographic (CXR) pleural opacification: analysis results
Common OR (95% CI) p-value
Treatment effect across all time pointsa 0.77 (0.45 to 1.34) 0.36
a 115 (70) and 125 (75) participants in the control and intervention groups, respectively, included in analysis.
TABLE 18 Degree of visible lung entrapment on CXR at 6 months: summary measures
Time point and degree of
entrapment
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
6 months 35 (21) included 37 (23) included
No lung entrapment 35 (100) 37 (100)
Minor lung entrapment (1–24%
unexpanded lung)
0 (0) 0 (0)
Moderate lung entrapment (25–49%
unexpanded lung)
0 (0) 0 (0)
Severe lung entrapment (≥ 50%
unexpanded lung)
0 (0) 0 (0)
TABLE 16 Categorical version of percentage radiographic (CXR) pleural opacification: summary measures
Time point and degree of
specification
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
Drain removal/discharge 105 (63) included 98 (60) included
No fluid visible 18 (17) 12 (12)
1–24% opacification 66 (63) 58 (59)
25–49% opacification 20 (19) 23 (23)
≥ 50% opacification 1 (1) 5 (5)
1 month 89 (54) included 76 (46) included
No fluid visible 7 (8) 1 (1)
1–24% opacification 44 (49) 42 (55)
25–49% opacification 29 (33) 27 (36)
≥ 50% opacification 9 (10) 6 (8)
3 months 65 (39) included 47 (29) included
No fluid visible 8 (12) 6 (13)
1–24% opacification 36 (55) 25 (53)
25–49% opacification 14 (22) 14 (30)
≥ 50% opacification 7 (11) 2 (4)
6 months 35 (21) included 37 (23) included
No fluid visible 5 (14) 8 (22)
1–24% opacification 22 (63) 21 (57)
25–49% opacification 6 (17) 7 (19)
≥ 50% opacification 2 (6) 1 (3)
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TABLE 20 Clinical outcomes in patients who did not receive talc
Outcome
Treatment arm, n/N
Thoracoscopy and poudrage
(N= 1)
Chest drain and slurry
(N= 18)
Pleurodesis failure 90 days (primary outcome)a 0/1 6/16
Mortality within 180 days 0/1 13/18
a Outcome missing for two patients in control arm.
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FIGURE 8 Thoracic pain VAS over the first 7 days post randomisation.
TABLE 19 Summary of delay from randomisation to allocated procedure
Number of days
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)a
Chest drain and slurry
(N= 164)b
0 126 (77) 146 (89)
1 20 (12) 17 (10)
2 11 (7) 1 (1)
3 5 (3) 0 (0)
4 0 (0) 0 (0)
5 1 (1) 0 (0)
6 1 (1) 0 (0)
a 164 (99) included.
b 164 (100) included.
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Adverse events and serious adverse events
Adverse events
A summary of all recorded AEs can be found in Table 21.
In the control arm, 80 out of 164 (49%) participants experienced at least one AE compared with 91 out of
166 (55%) participants in the intervention arm. A summary of the number of participants experiencing
multiple events can be found in Table 22.
There was no significant difference between the groups in the number of AEs recorded at 7, 30 or
180 days (Table 23).
Serious adverse events
A summary of all recorded SAEs can be found in Table 24.
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FIGURE 9 Dyspnoea VAS over the first 7 days post randomisation.
TABLE 21 Summary of AEs by type
AE
Treatment arm (n)
Thoracoscopy and poudrage
(N= 179)
Chest drain and slurry
(N= 152)
Accidental injury 3 2
Anaemia 10 4
Cardiac arrhythmia 2 2
Cerebrovascular event 0 2
Disease progression: death 7 5
Disease progression: dyspnoea due to fluid 23 20
Disease progression: dyspnoea not due to fluid 4 4
Disease progression: metastatic disease 7 5
Disease progression: nausea/vomiting 2 2
Disease progression: other 2 1
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TABLE 21 Summary of AEs by type (continued )
AE
Treatment arm (n)
Thoracoscopy and poudrage
(N= 179)
Chest drain and slurry
(N= 152)
Disease progression: pain 0 3
Drain blockage (IPC) 1 1
Drain dislodgement/accidental removal 2 9
Lung entrapment 4 1
Medication/chemotherapy side effect 9 13
Non-chest infection 7 5
Other abnormal blood tests 1 0
Other AE/unspecified 1 0
Other pleural intervention related: pleural
infection
0 2
Other pleural intervention related:
pneumothorax/bronchopleural fistula
15 18
Other venous thromboembolic event 0 2
Pneumonia/chest infection 25 19
Pulmonary embolism 7 9
Trial intervention related: other/unspecified 10 7
Trial intervention related: bleeding 2 1
Trial intervention related: cough 1 0
Trial intervention related: hypoxia 4 0
Trial intervention related: pain 9 6
Trial intervention related: pleural infection 6 0
Trial intervention related: pneumothorax/
bronchopleural fistula
3 4
Trial intervention related: subcutaneous infection 3 3
Trial intervention related: surgical emphysema 9 2
TABLE 22 Summary of AEs by frequency of occurrence
Summary measure
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
At least one AE 91 (55) 80 (49)
Number of AEs per patient
0 75 (45) 84 (51)
1 43 (26) 39 (24)
2 27 (16) 24 (15)
3 7 (4) 7 (4)
4 11 (7) 7 (4)
5 2 (1) 2 (1)
6 0 (0) 1 (1)
7 1 (1) 0 (0)
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TABLE 23 Analysis of AEs by trial time point
AE by time point
Treatment arm, summary measure, n (%)
OR
(95% CI) p-value
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
AE within 7 days 50 (30) 43 (26) 1.21 (0.74 to 1.97) 0.45
AE within 30 days 61 (37) 60 (37) 1.00 (0.63 to 1.57) 0.99
AE within 180 days 89 (54) 77 (47) 1.31 (0.84 to 2.03) 0.23
TABLE 24 Summary of SAEs by type
SAE
Treatment arm (n)
Thoracoscopy and poudrage
(N= 64)
Chest drain and slurry
(N= 54)
Accidental injury 0 1
Anaemia 1 1
Cerebrovascular event 0 2
Disease progression: death 11 12
Disease progression: dyspnoea due to fluid 6 8
Disease progression: dyspnoea not due to fluid 4 1
Disease progression: metastatic disease 6 1
Disease progression: nausea/vomiting 2 0
Drain blockage (non-IPC) 1 1
Drain dislodgement/accidental removal 0 1
Lung entrapment 1 0
Medication/chemotherapy side effect 1 2
Non-chest infection 2 0
Other abnormal blood tests 1 2
Other AE/unspecified 3 1
Other venous thromboembolic event 0 1
Pneumonia/chest infection 10 7
Pulmonary embolism 2 3
Trial intervention related: other/unspecified 2 1
Trial intervention related: bleeding 1 2
Trial intervention related: hypoxia 4 0
Trial intervention related: pain 0 1
Trial intervention related: pleural infection 5 2
Trial intervention related: pneumothorax/
bronchopleural fistula
0 3
Trial intervention related: subcutaneous infection 1 1
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In the control arm, 44 out of 164 (27%) participants experienced at least one SAE compared with 46 out
of 166 (28%) participants in the intervention arm. A summary of the number of participants experiencing
multiple events can be found in Table 25.
There was no significant difference between the groups in the number of SAEs recorded at 7, 30 or
180 days (Table 26).
TABLE 25 Summary of SAEs by frequency of occurrence
SAE
Treatment arm, n (%)
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
At least one SAE 46 (28) 44 (27)
Number of SAEs per patient
0 120 (72) 120 (73)
1 30 (18) 35 (21)
2 14 (8) 8 (5)
3 2 (1) 1 (1)
TABLE 26 Analysis of SAEs by trial time point
SAE by time point
Treatment arm, summary measure, n (%)
OR (95% CI) p-value
Thoracoscopy and poudrage
(N= 166)
Chest drain and slurry
(N= 164)
SAE within 7 days 17 (10) 15 (9) 1.13 (0.54 to 2.35) 0.75
SAE within 30 days 26 (16) 26 (16) 0.98 (0.54 to 1.78) 0.94
SAE within 180 days 46 (28) 44 (27) 1.04 (0.64 to 1.70) 0.88
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Chapter 5 Health economic evaluation results
Quality of life
Responses to the EQ-5D-5L are reported in Appendix 2 (see Table 34). These responses were then
converted into utilities (Table 27). There were no statistically significant differences in utilities or VAS scores
at any of the three follow-up time points.
Summary scores for each of the eight domains of the SF-36 are presented in Appendix 2 (see Table 35).
There were no statistically significant differences in scores between the two groups at any of the three
follow-up time points. In addition, there were no differences in the two summary scores (physical component
score and mental health component score). As with the EQ-5D-5L, there were no differences in SF-6D utilities
between the two patient groups in any of the follow-up time points (see Table 27).
Survival data were combined with EQ-5D-5L utilities to estimate QALYs at 6 months after randomisation.
Patients randomised to thoracoscopy-delivered talc poudrage gained, over 6 months, an average of 0.246
(95% CI 0.227 to 0.263) QALYs compared with 0.239 (95% CI 0.217 to 0.258) in those patients randomised
to standard chest tube talc slurry pleurodesis. This resulted in a non-significant increase of 0.007 (95% CI
difference –0.019 to 0.034) QALYs in patients randomised to thoracoscopy-delivered talc poudrage.
TABLE 27 The EQ-5D-5L, VAS and SF-6D utilities
Quality-of-life measure
Treatment arm, mean (SD), n
p> |z|
Mean difference
(95% CI)Thoracoscopy and poudrage Chest drain and slurry
EQ-5D-5L utility
Randomisation 0.57 (0.26), 163 0.55 (0.26), 164 0.571 0.02 (–0.04 to 0.07)
1 month 0.60 (0.26), 132 0.60 (0.27), 132 0.892 0.00 (–0.06 to 0.07)
3 months 0.60 (0.29), 95 0.65 (0.27), 100 0.227 –0.05 (–0.13 to 0.04)
6 months 0.71 (0.22), 69 0.68 (0.26), 72 0.307 0.04 (–0.04 to 0.12)
VAS
Randomisation 50 (22), 160 50 (22), 164 0.791 1 (–4 to 6)
1 months 59 (23), 132 55 (25), 132 0.238 4 (–2 to 9)
3 months 63 (23), 95 60 (23), 98 0.408 3 (–4 to 9)
6 months 66 (23), 70 66 (21.4), 71 0.980 0 (7 to 8)
SF-6D utility
Randomisation 0.58 (0.11), 157 0.56 (0.12), 153 0.265 0.01 (–0.01 to 0.04)
1 months 0.59 (0.11), 125 0.60 (0.12), 123 0.782 0.00 (–0.03 to 0.03)
3 months 0.63 (0.11), 89 0.64 (0.14), 96 0.903 0.00 (–0.04 to 0.03)
6 months 0.65 (0.12), 67 0.64 (0.12), 71 0.769 0.01 (–0.03 to 0.05)
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Resource use
Initial hospitalisation
We evaluated initial length of stay for both participant groups. This was calculated from date of admission
(as opposed to date of randomisation) to date of discharge. We had missing data on dates of discharge or
admission for two participants. For a further four participants, we had missing data on the specialty wards
they had been admitted to, so we were be unable to obtain initial hospitalisation costs for these four
participants. As a result, data were missing for six participants.
Participants randomised to thoracoscopy-delivered talc poudrage had an initial length of stay of 6.366
(SD 10.800, n = 164) days compared with 6.794 (SD 6.679, n = 160) days for participants randomised to
standard chest tube talc slurry pleurodesis. This was a non-significant difference of 0.428 days (95% CI
difference –1.540 to 2.396 days; p = 0.669).
Follow-up resource use
Information on 1-, 3- and 6-month resource use is presented in Appendix 2. Table 28 presents the mean NHS
resource-use estimates over the 6 months after randomisation, evaluated using available-case analysis. There
were no statistically significant differences in NHS or hospice care resource-use consumption patterns
between the two participant groups over the 6 months after randomisation.
Additional data regarding resource use may be found in Appendix 2 (see Tables 36 and 37).
TABLE 28 Follow-up resource use up to 6 months
Type of resource use
Treatment arm, mean (95% CI)
Mean difference
(95% CI)Thoracoscopy and poudrage Chest drain and slurry
General practice consultations
Surgery 1.6 (1.3 to 1.8) 1.8 (1.4 to 2.1) –0.2 (–0.6 to 0.2)
Home 0.7 (0.5 to 0.8) 0.6 (0.1 to 0.9) 0.1 (–0.3 to 0.3)
Telephone 1.0 (0.7 to 1.2) 0.8 (0.6 to 1.1) 0.2 (–0.2 to 0.5)
Outpatient visits 5.5 (4.7 to 6.2) 5.8 (5.2 to 6.6) –0.3 (–1.4 to 0.6)
A&E visits 0.5 (0.4 to 0.6) 0.5 (0.4 to 0.6) 0.0 (–0.2 to 0.2)
Ambulance use 0.2 (0.1 to 0.3) 0.3 (0.2 to 0.4) –0.1 (–0.2 to 0.1)
Hospitalisations 1.1 (0.9 to 1.2) 0.9 (0.8 to 1.1) 0.2 (–0.1 to 0.3)
Length of stay (days) 6.7 (5.4 to 8.0) 5.5 (4.3 to 6.8) 1.2 (–0.5 to 3.0)
Hospice care
Length of stay (days) 1.5 (0.6 to 2.5) 1.1 (0.3 to 2.3) 0.4 (–1.1 to 1.6)
Hospice nurse visits 0.8 (0.2 to 1.8) 0.6 (0.4 to 0.9) 0.2 (–0.5 to 1.1)
Nurse consultations
Clinic 2.3 (1.8 to 2.8) 2.9 (2.4 to 3.5) –0.6 (–1.4 to 0.1)
Home 6.6 (4.1 to 9.3) 7.0 (4.9 to 9.1) –0.4 (–3.9 to 3.0)
Physiotherapist visits 0.3 (0.1 to 0.5) 0.2 (0.1 to 0.3) 0.1 (–0.1 to 0.3)
Occupational therapist visits 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3) 0.0 (–0.1 to 0.2)
Psychologist visits 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.1) 0.0 (–0.1 to 0.1)
Counsellor visits 0.1 (0.0 to 0.2) 0.1 (0.0 to 0.2) 0.0 (–0.1 to 0.1)
Day hospital visits 1.3 (0.9 to 1.8) 2.0 (1.3 to 2.9) –0.7 (–1.6 to 0.2)
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Costs
Procedure costs
Table 29 details the per-patient costs of performing each of the two trial interventions. On average, for the
procedures observed, participants randomised to standard chest tube talc slurry pleurodesis remained in
theatre for 31 minutes while the drain was inserted. In addition, these participants required an additional
30 minutes for talc installation, but this was not undertaken in theatre. Participants randomised to
thoracoscopy-delivered talc poudrage remained in theatre for 70 minutes. Per-patient costs of thoracoscopy-
delivered talc poudrage were £1273, compared with £753 for standard chest tube talc slurry pleurodesis.
Overall costs
Information on costs accrued by participants at the 1-, 3- and 6-month follow-ups are reported in
Appendix 2. Table 30 presents mean total NHS and hospice care costs over the 6 months after
randomisation, evaluated using available-case analysis. As shown, there were no statistically significant
differences in NHS or hospice care costs between the two participant groups over the 6 months after
randomisation.
Over 6 months, participants randomised to thoracoscopy-delivered talc poudrage incurred mean costs of
£10,687 (95% CI £9621 to £11,627) per participant compared with £10,146 (95% CI £9119 to £11,212)
for participants randomised to standard chest tube talc slurry pleurodesis. As a result, participants
randomised to thoracoscopy-delivered talc poudrage incurred additional costs of £541, over 6 months,
compared with participants randomised to standard chest tube talc slurry pleurodesis, an increase that was
not found to be significant (95% CI difference –£9533 to £1933).
Further data regarding costs may be found in Appendix 2 (see Tables 38 and 39).
Cost-effectiveness
Mean QALY gain was 0.239 in the standard chest tube talc slurry pleurodesis group and 0.246 in the
thoracoscopy-delivered talc poudrage group, a mean difference of 0.007 (95% CI –0.019 to 0.034)
(Table 31).
TABLE 29 Calculated per-patient costs for each procedure
Reason for cost
Treatment arm, cost (£)
Thoracoscopy and poudrage Chest drain and slurry
Theatre usage 407 158
Medical staff 545 290
Equipment for thoracoscopy 42 0
Disposables 52 80
Medication and sedation 9 7
Investigation 218 218
Total cost 1273 753
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TABLE 30 Mean NHS costs at 6 months
Type of resource use
Treatment arm, mean cost (£) (95% CI)
Mean difference
(£) (95% CI)Thoracoscopy and poudrage Chest drain and slurry
Initial hospitalisation 2796 (2298 to 3374) 2901 (2534 to 3309) –105 (–928 to 718)
Intervention costs 1273 (N/A) 753 (N/A) 520 (N/A)
General practice consultations
Surgery 57 (47 to 66) 63 (52 to 76) –6 (–23 to 7)
Home 60 (43 to 79) 56 (38 to 78) 4 (–24 to 31)
Telephone 27 (20 to 34) 23 (17 to 30) 4 (–6 to 14)
Outpatient visits 684 (593 to 774) 736 (650 to 824) –52 (–175 to 70)
A&E visits 70 (54 to 86) 71 (55 to 88) –1 (–24 to 21)
Ambulance use 44 (31 to 60) 57 (40 to 76) –13 (–37 to 10)
Follow-up hospitalisations 3657 (2906 to 4397) 3124 (2459 to 3870) 533 (–478 to 1569)
Hospice care
Hospice admissions 578 (231 to 979) 436 (117 to 898) 142 (–428 to 649)
Hospice nurse visits 92 (26 to 199) 69 (42 to 98) 23 (–55 to 125)
Nurse consultations
Clinic 32 (26 to 40) 41 (34 to 49) –9 (–20 to 1)
Home 269 (166 to 382) 286 (200 to 372) –17 (–158 to 121)
Physiotherapist visits 14 (7 to 24) 11 (6 to 17) 3 (–6 to 14)
Occupational therapist visits 15 (9 to 23) 15 (7 to 23) 0 (–10 to 11)
Psychologist visits 10 (0 to 25) 10 (2 to 21) 0 (–15 to 16)
Counsellor visits 17 (3 to 32) 17 (5 to 31) 0 (–20 to 19)
Day hospital visits 988 (685 to 1336) 1475 (961 to 2113) –487 (–1207 to 156)
Total costs 10,687 (9621 to 11,627) 10,146 (9119 to 11,212) 541 (–953 to 1933)
N/A, not applicable.
TABLE 31 Cost-effectiveness
Summary measure
Treatment arm, mean (95% CI)
Mean difference
(95% CI)Thoracoscopy and poudrage Chest drain and slurry
Total costs (£) 10,687 (9621 to 11,627) 10,146 (9119 to 11,212) 541 (–953 to 1933)
Total QALYs 0.246 (0.227 to 0.263) 0.239 (0.217 to 0.258) 0.007 (–0.019 to 0.034)
ICER (£) 77,286
Probability talc poudrage is cost-effective
£20,000 threshold 0.36
£50,000 threshold 0.45
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Therefore, the incremental cost per QALY gained when thoracoscopy-delivered talc poudrage was
compared with standard chest tube talc slurry pleurodesis was £77,286. At the conventional £20,000 per
QALY gained threshold, thoracoscopy-delivered talc poudrage would have a 0.36 probability of being
cost-effective (Figure 10). The cost-effectiveness plane shows that, of the 1000 simulations, 36% fall below
the £20,000 per QALY willingness-to-pay threshold. If we apply the NICE end-of-life criteria, with the
willingness-to-pay threshold rising to £50,000 per QALY, the probability that thoracoscopy-delivered talc
poudrage is cost-effective rises to 0.45, with this probability rising to 0.54 at a willingness-to-pay threshold
of £100,000 per QALY gained (Figure 11).
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FIGURE 10 Cost-effectiveness plane. WTP, willingness to pay.
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FIGURE 11 Cost-effectiveness acceptability curve. WTP, willingness to pay.
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Sensitivity analysis
When the time to perform thoracoscopy-delivered talc poudrage was reduced from 70 to 60 minutes, the costs
of the intervention fell from £1273 to £1137. As a result, mean total NHS and hospice care costs at 6 months
for participants randomised to thoracoscopy-delivered talc poudrage reduced to £10,513 (95% CI £9485 to
£11,495). Therefore, the mean cost difference between participants randomised to thoracoscopy-delivered
talc poudrage and those participants randomised to standard chest tube talc slurry pleurodesis was £346
(95% CI difference –£1089 to £1798). This resulted in an incremental cost per QALY gained of £49,429,
when thoracoscopy-delivered talc poudrage was compared with standard chest tube talc slurry pleurodesis.
At the conventional £20,000 per QALY gained threshold, thoracoscopy-delivered talc poudrage would have
a 0.41 probability of being cost-effective. Using NICE’s end-of-life criteria (i.e. a threshold of £50,000 per
QALY gained), the probability that thoracoscopy-delivered talc poudrage is cost-effective would be 0.50.
Multiple imputation of missing data
After multiple imputation of missing EQ-5D-5L utility values, average utilities at each follow-up were found
to be lower than in the complete-case analysis (Table 32). As in the available-case analysis, differences in
utility also remained non-significant between the two treatment groups. However, at the 3- and 6-month
follow-up, mean differences between groups varied between the available-case analysis and the multiple
imputation analysis (–0.05 vs. –0.07 at 3 months, respectively, and 0.04 vs. 0.02 at 6 months, respectively).
After survival data were combined with EQ-5D-5L utilities obtained in the multiple imputation analysis, the
difference in QALYs gained when thoracoscopy-delivered talc poudrage was compared with standard chest
tube talc slurry pleurodesis was 0.00007 (i.e. 0.22336 QALYs for thoracoscopy and 0.22328 QALYs for
standard chest).
After multiple imputation, we found that thoracoscopy-delivered talc poudrage was £361 (95% CI difference
–£1257 to £1979) more costly than standard chest tube talc slurry pleurodesis per patient (Table 33).
This difference was smaller than the £541 (95% CI difference –£953 to £1933) difference observed in the
available-case analysis.
As the multiple imputation analysis results showed virtually no difference in QALYs gained between the
two treatment groups, the incremental cost per QALY gained when thoracoscopy-delivered talc poudrage
was compared with standard chest tube talc slurry pleurodesis was in excess of £4M in the multiple
imputation analysis.
TABLE 32 The EQ-5D-5L utility after multiple imputation of missing cases
Time point
Treatment arm, mean (SD), n
p> |z|
Mean difference
(95% CI)Thoracoscopy and poudrage Chest drain and slurry
Randomisation 0.57 (0.25), 166 0.55 (0.26), 164 0.571 0.02 (–0.04 to 0.07)
1 month 0.58 (0.27), 156 0.58 (0.28), 150 0.670 0.01 (–0.06 to 0.07)
3 months 0.53 (0.32), 131 0.60 (0.31), 122 0.563 –0.07 (–0.13 to 0.04)
6 months 0.60 (0.33), 102 0.59 (0.33), 98 0.728 0.02 (–0.06 to 0.12)
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TABLE 33 Mean NHS costs at 6 months after multiple imputation of missing cases
Reason for cost
Treatment arm, mean (£)
Mean cost (£)
difference (95% CI)Thoracoscopy and poudrage Chest drain and slurry
Initial hospitalisation 2792 2902 –111 (–925 to 703)
Intervention costs 1273 753 520 (N/A)
General practice consultations 145 140 5 (–37 to 47)
Follow-up hospitalisation costs 4868 4971 –103 (–1510 to 1340)
Hospice and nursing care 480 427 53 (–206 to 311)
Other health-care costs 48 51 –2 (–37 to 32)
Total costs 9606 9245 361 (–1257 to 1979)
N/A, not applicable.
DOI: 10.3310/hta24260 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 26
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Bhatnagar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53

Chapter 6 Discussion and conclusions
Summary of main trial findings
The TAPPS trial achieved its recruitment target of 330 participants. The results appear to be conclusive, in
that there was no evidence of any difference between the two treatment arms in the primary outcome
measure, pleurodesis failure at 90 days post randomisation. Indeed, there was no suggestion of a difference
in any of the secondary outcome measures, including pleurodesis failure up to the final follow-up visit at
180 days post randomisation, mortality, time spent in hospital, radiological appearances or patient-reported
outcomes. Sensitivity analyses supported the findings for the primary outcome, and it is improbable that
missing data led to a significant effect.
Absolute values for pleurodesis failure were low (approximately 23% in both arms) at 90 days. Previous
literature has suggested 30-day failure rates of approximately 10% for poudrage, which is in line with our
findings.5,25 Interestingly, we also saw a similarly low rate of failure in those participants treated with slurry.
This is at odds with previous reports25 and may be because our trial took place in clinical environments where
there are more varied treatment options, including IPCs, meaning that those participants being considered
for inpatient pleurodesis may be a subtly different population to those participants included in earlier studies.
Prespecified subgroup analyses did not reveal any differences in treatment effect by baseline performance
status or underlying malignancy type. A significant interaction was noted for participants on steroids at
baseline; however, participants numbers for this analysis were small. Estimated treatment effects were
different between those participants on anticancer treatment at baseline and those participants not on
anticancer treatment (OR 1.96 vs. 0.65), although the interaction was not statistically significant (p = 0.08)
and, once again, participant numbers in this subgroup were small.
Approximately 50% of participants in the trial experienced an AE during their participation, with half of
these experiencing an event that was classified as serious (including death). The majority of events were
unrelated to the trial interventions, typically being associated with progression of the underlying malignancy.
No difference in the numbers, or timings, of AEs or SAEs was noted between the treatment groups.
Summary of health economic findings
The results of the economic evaluation of the TAPPS trial are in line with those results of the effectiveness
analysis, in that there is no clear evidence suggesting that either of the two interventions is superior in terms of
costs or quality-adjusted life expectancy. However, the incremental cost-effectiveness analysis suggests that
LAT and talc poudrage was not cost-effective when compared with talc slurry pleurodesis at current standard
NICE thresholds of cost-effectiveness (£20,000 per QALY gained), with a likelihood of 0.36 of poudrage being
superior. Applying a higher threshold of £50,000 per QALY gained (which has been suggested by NICE for
patients who are in the palliative stages of treatment) increases the probability that poudrage is cost-effective
(to 0.45), but the overall likelihood remains less probable than slurry being the more cost-effective method.
There are, however, limitations to the above. Primarily due to patients dying in between follow-ups and,
to a lesser degree, withdrawing from the trial, there were missing data, particularly with regard to follow-up
costs. We tried to minimise missing resource-use data by asking clinical staff to complete some of the questions,
including those patients asking about ambulance and A&E use, outpatient visits and hospitalisations, through
review of patients’ hospital records. As a result, rather than reduce our sample size even further by restricting our
analysis to patients with complete-case information (i.e. had to have information on all resource-use items
and quality-of-life estimates), we used an available-case analysis to determine mean costs and quality-of-life
DOI: 10.3310/hta24260 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 26
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Bhatnagar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
estimates. In addition to this, we also performed a sensitivity analysis using multiple imputation methods.
This analysis also confirmed that thoracoscopy-delivered talc poudrage is unlikely to be cost-effective, as the
ICER after this analysis was in excess of £4M.
Trial strengths
The trial was conducted and reported in line with CONSORT recommendations. To the best of our knowledge,
the TAPPS trial is the first RCT to examine the efficacy of talc poudrage delivered at LAT compared with
traditional talc slurry. It addresses a clear and important area of uncertainty in clinical practice and has
been able to inform this in a robust manner. The trial processes, including randomisation and treatment
allocations, were robustly designed, with the likelihood of bias minimised as far as possible, and the trial
interventions were performed in a standardised fashion that is reflective of current practice, meaning that
the results are likely to be generalisable to the wider population.
The two treatment groups were well matched at baseline, with a distribution of malignancies in line
with previous data. Retention to follow-up was high; thus, the trial was suitably powered to address the
primary research question. The primary outcome was assessed at a time point of significant relevance to
both patients and carers, with its definition robust, pragmatic and clinically meaningful to modern UK
practice. The analysis took place using the intention-to-treat principle and followed a prespecified plan that
was assessed and approved by the TSC. We performed a comprehensive sensitivity analysis, which supports
the primary outcome finding, and ensured that any potentially controversial decisions relating to reporting
the primary outcome were assessed in a blinded fashion. The secondary outcomes and subgroup analyses
were chosen to examine both previous studies’ findings and important supplementary clinical questions.
We also performed a comprehensive health economic analysis – the first of its kind in the trial population
and interventions under investigation. This analysis was performed from the perspective of the NHS and
so, as for the effectiveness analysis, the results are likely to be able to inform current UK practice.
Trial limitations
The trial entry criteria specified that patients be sufficiently fit to undergo LAT under light sedation,
which may reduce the degree of generalisability of the results to those patients presenting with a greater
degree of frailty (who do not wish to undergo IPC insertion).
The trial was conducted on an open-label basis, as it was not deemed feasible or ethical to blind
participants and/or perform sham procedures, which may have influenced the results of patient-reported
measures, such as pain or breathlessness. In additional, due to the organisation of most recruiting centres,
it is probable that those clinicians responsible for the recruitment and trial interventions were also required
to assess participants for pleurodesis failure, introducing the potential for bias (although this was
considered and addressed through blinded reassessment, as above).
The duration of follow-up was limited to 6 months. For participants with a certain malignancy, such as
mesothelioma or breast cancer, this may not have been long enough a period to fully inform care over
the duration of what may be a longer average survival period. The follow-up period may also have
had an impact on the health economic evaluation, as it did not encompass the whole remaining life
of the participant, meaning longer-term projections regarding costs cannot be made. However, at
6 months, > 65% of the trial participants had died and prognosis for 6-month survivors was poor. As a
result, we believe that the main impact of the interventions under study, both in terms of costs and
outcomes, were captured.
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Recruitment challenges
Although the trial achieved its target, this was only possible as a result of an extension in the recruitment
period and site numbers to accommodate lower than expected accrual, the original predicted requirements
being 3 years and eight centres, respectively. During the course of the trial, close liaison with PIs and
scrutiny of screening logs revealed a range of potential reasons for this disparity. These included:
l Patients declining enrolment, largely influenced by the significant comorbidities and degree of symptoms
that most MPE patients experience, but also by preconceptions of research and previous clinical
encounters.
l Patients favouring one treatment arm over the other after reading trial information, and thus declining
randomisation. This effect did not appear to favour either treatment arm, with the patient information
sheet carefully written to express equipoise, suggesting individual patient preference was key.
l Patients favouring IPC to pleurodesis approach. As an increasing number of centres became able,
and willing, to offer IPCs to patients during the trial period (an effect which could not have been
predicted at the time of the original grant application), it was, perhaps, inevitable that some patients
who historically could not have been offered a treatment choice would elect to have an IPC placed
over a talc pleurodesis.
l Patients being admitted and managed for the MPE acutely, thereby missing recruitment windows.
This appeared to be an issue that varied according to the pre-established referral and patient discovery
pathways at individual sites, with the effect being compounded if there was a lack of pleural-specific
personnel on site.
l Patients needing a tissue diagnosis. This appeared to be the most common reason for patients not
being enrolled into the TAPPS trial and was, perhaps, the most predictable. Given that the vast majority
of medical thoracoscopy is undertaken for the diagnosis of first-presentation pleural effusions, it was
always expected that the numbers of patients who would be enrolled to the trial, for purely therapeutic
treatment, would be relatively low. There also appeared to be an increasing trend in certain centres for
oncology colleagues to request thoracoscopic biopsies for all those patients with an effusion, regardless
of established diagnosis, to facilitate novel tumour marker discovery, which may, theoretically, alter
treatment. This practice meant that some of those patients, who traditionally would have needed only
a pleurodesis and, hence, would be eligible for trial inclusion, had to be excluded on the grounds
that they could not ethically be randomised to chest drain and slurry.
Patient and public involvement
Patient and public involvement in the TAPPS trial occurred in two distinct phases.
First, the main trial protocol, patient information sheets and consent forms were developed and approved
with input from the lay members of the TSC, both of whom were relatives of patients who had suffered
with MPE.
Second, these members remained a key part of the ongoing trial management, participating in all TSC
meetings and contributing from a non-medical perspective to ensure that the trial maintained its priorities of
being patient focused and pragmatic. In addition, during the course of the trial, a non-specialist summary
was prepared in conjunction with medical writers at Cancer Research UK. This summary was made publicly
available and ensured that the trial questions and aims were sufficiently approachable for a general audience.
Conclusions: interpretation of results
The results of the primary analysis have robustly demonstrated that there is no additional benefit in
performing talc poudrage at LAT over bedside chest drain and talc slurry for the management of MPE.
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This finding is in line with that noted in the Dresler et al. study,25 although, in contrast, we were unable
to demonstrate any signal for greater effectiveness of poudrage in any particular malignant subgroup. In
additional, no differences were found to suggest that there are advantages to either treatment with regard
to time spent in hospital or procedural safety.
When applying a standard NICE treatment threshold of £20,000 per QALY gained, the results of the
economic evaluation of the TAPPS trial would suggest that poudrage at LAT is unlikely to be a cost-effective
way to deliver talc. Applying the higher £50,000 threshold suggested that for palliative patients (which is
likely to be the best descriptor of the patients included in this trial), poudrage remains less likely to be
cost-effective, but by a much smaller margin.
Overall, the TAPPS trial has been unable to demonstrate any evidence to support choosing talc poudrage
over talc slurry for inducing a pleurodesis in patients with MPEs.
Future research and the management pathway for malignant
pleural effusion
Despite the rise of newer approaches to the management of MPE in the UK, talc pleurodesis – and in
particular inpatient talc pleurodesis as studied in the TAPPS trial – remains an important option for what is
likely to be the majority of patients. When considering the wider context, beyond the NHS, safe outpatient
management of MPE is not, as yet, achievable in most health-care environments, making these results all
the more pertinent.
In the UK, it is now widely accepted that patients be offered the choice of how they wish their MPE to
be managed: either as an outpatient with an IPC or as an inpatient with an attempt at talc pleurodesis,
although it must be noted that, to the best of our knowledge, there have not been any trials comparing
inpatient and outpatient methods powered to examine pleurodesis success as the primary outcome.
For those patients choosing an inpatient approach (i.e. an explicit attempt at preventing further fluid),
the TAPPS trial would not support choosing medical thoracoscopy and poudrage over traditional talc slurry.
There may be, however, other reasons to perform a thoracoscopy, including the acquisition of further
tissue for targeted anticancer therapy.
There remain a number of important research questions relating to the ‘best’ way to manage patients
presenting with symptomatic MPE. Treatment combinations and hybrid pathways are increasingly being
considered, allowing for greater personalisation and adaptation to a patient’s needs. RCTs, potentially
multiarm, that incorporate the use of an IPC alone, an IPC in combination with talc slurry or an IPC
placed at the time of a diagnostic thoracoscopy (for example), and that compare these treatments to
‘traditional’ approaches, may be informative. To complement any such study, it would be vital to gather
comprehensive health economic data to clarify which treatments are likely to be cost-effective. Indeed,
for understanding costs, a prospective observational design may be sufficient and would also allow the
possibility of examining less-used, locally bespoke pathways or those patients who choose to undergo
non-definitive treatments, such as repeat thoracentesis.
DISCUSSION AND CONCLUSIONS
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Appendix 1 The TAPPS trial standard operating
procedures for talc slurry and talc poudrage
Trial-specific procedure for drain insertion (control arm)
Drain insertion
l Procedure ideally to be performed in dedicated clean environment (e.g. theatre, procedure room).
l Explain procedure.
l Obtain written consent for Seldinger drain insertion.
l Position patient and administer sedation as necessary.
l Perform thoracic ultrasonography to confirm safe site for drain insertion.
l Prepare kit, including filling drainage bottle to pre-marked prime line.
l Don sterile gown and gloves and sterilise insertion site using appropriate skin preparation.
l Infiltrate local anaesthetic to skin and down to pleura.
l Insert 10–14 French chest drain, using Seldinger technique.
l Attach the provided three-way adaptor to the drain and screw in the tubing adaptor.
l Secure to the skin.
l Apply a small amount of gauze padding around the drain insertion site to prevent discomfort.
l Fix to the skin using clear dressings. The insertion site should ideally be visible.
l Attach the drain to the underwater seal using the sterile tubing provided.
l Fully document procedure and drainage plan in patient notes.
l Ensure the patient is prescribed adequate analgesia and intrapleural flushes to maintain drain patency
(20 ml of 0.9% saline three times daily).
l Observations, including drainage volumes, should be performed at least every hour for the 2 hours post
insertion, reverting to standard frequency if there are no significant complications.
l A CXR should be performed to ensure adequate positioning.
Drainage plan
l Clamp/close the drain once 1000 ml is reached, if the patient experiences distress during drainage,
or once 1 hour has passed post insertion.
l Ensure the drain is clamped/closed for a minimum of 1 hour before further drainage is allowed.
l Drainage volumes are to be charted at least every 8 hours for the duration of drain use.
Trial-specific procedure for slurry instillation (control arm)
Talc slurry pleurodesis
l Procedure may be performed at the patient’s bedside as long as aseptic technique is maintained.
l Explain procedure.
l Administer premedication (e.g. 10 mg of oral morphine solution).
l Position the patient comfortably, allowing access to the drain.
l Expose the three-way tap.
l Clean the access port using an alcohol-based swab.
l Instil 10 ml of sterile 0.9% saline into the pleural cavity via the three-way tap to ensure drain patency.
l Instil 3 mg/kg (maximum 250 mg) of 1% lidocaine hydrochloride in to the pleural space via the
three-way tap.
l Turn the tap off to the drain (clamp) for 10 minutes.
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l Make up 4 g of sterile talc to a slurry using 50 ml of 0.9% sterile saline.
l Instil the slurry in to the pleural cavity via the three-way tap at least 10 minutes after lidocaine hydrochloride
instillation.
l Flush 20 ml of 0.9% saline into the pleural cavity via the three-way tap.
l Turn the tap off to the drain (clamp) for 2 hours.
l Re-open the three-way tap to both the drain and the drainage bottle.
l Apply thoracic suction (–10 to –20 cm water) for at least 24 hours.
l Ensure that the patient is prescribed adequate analgesia.
l Observations should be performed every 15 minutes for the first hour post talc, then hourly for the next
3 hours, before reverting to standard frequency if there are no significant complications.
l A CXR should be performed between 18 and 24 hours post talc instillation.
Post pleurodesis
l Drains should remain in place for at least 24 hours post talc slurry instillation.
l Drainage volumes should continue to be recorded at least every 8 hours.
l Once drainage volumes fall below 250 ml in the preceding 24 hours, the drain may be removed.
l A posterior–anterior CXR should be performed prior to the patient being discharged home.
Trial-specific procedure for medical thoracoscopy (intervention arm)
Thoracoscopy and poudrage
l Procedure ideally to be performed in dedicated theatre, endoscopy suite or ‘clean environment’
(e.g. dedicated procedure room).
l Explain procedure.
l Obtain written consent for medical thoracoscopy.
l Position patient and administer sedation as necessary.
l Perform thoracic ultrasonography to confirm safe site for port insertion.
l Prepare kit, including filling drainage bottle to pre-marked prime line.
l Don sterile gown and gloves and sterilise insertion site using appropriate skin preparation.
l Infiltrate local anaesthetic to skin and down to pleura.
l Make adequate skin incision.
l A closing suture should be placed either at this point or towards the end of the procedure.
l Create port site by dissecting down to pleura.
l Insert trocar and port before removing trocar to leave port in situ.
l Aspirate chest cavity to dryness using flexible suction catheter. Record total drainage volume.
l Perform thoracoscopy, including visual survey of chest cavity, pleural fluid collection, targeted biopsies
as necessary and breakdown of minor adhesions if safe to do so.
l At the end of the procedure spray 4 g of sterile talc over the pleural surface using a poudrage kit,
aiming for an even spread of talc. Ensure that there is enough space left around the delivery tube/needle
to allow air to escape (to avoid inducing a tension pneumothorax).
l Remove the thoracoscopy port and insert a 16–24 French chest drain via the port tract.
l Secure drain in place and apply appropriate dressings.
l Consider attaching a chest drain adaptor [e.g. Thal-Quick Chest Tube Adaptor (Cook Medical;
Bloomington, IN, USA)] to allow easy pleural access without disconnecting the drain.
l Attach to an underwater drainage bottle using sterile tubing.
l Admit to ward and ensure adequate analgesia is prescribed.
l Connect to thoracic suction for at least 24 hours.
l A CXR should be performed to ensure adequate drain positioning.
l The drain should stay in place for at least 24 hours post poudrage.
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Post thoracoscopy
l Observations (pulse, temperature, blood pressure, saturations and respiratory rate) should be performed
every 15 minutes for the first hour post procedure, then hourly for the next 3 hours, before reverting to
standard frequency if there are no significant complications.
l A CXR should be performed between 18 and 24 hours post poudrage.
l Drainage volumes should be recorded at least every 8 hours.
l Once drainage volumes fall below 250 ml in the preceding 24 hours, the drain may be removed.
l A PA CXR should be performed prior to the patient being discharged home.
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Appendix 2 Additional information relating to
health economic analyses
TABLE 34 Quality of life: EQ-5D-5L responses
EQ-5D-5L domain
Time point, n (%)
Randomisation 1 month 3 months 6 months
Drain insertion and talc slurry
Mobility
No problems in walking about 37 (23) 38 (29) 33 (33) 23 (32)
Slight problems in walking about 37 (23) 23 (17) 20 (20) 20 (28)
Moderate problems in walking about 54 (33) 45 (34) 25 (25) 20 (28)
Severe problems in walking about 32 (20) 22 (17) 20 (20) 7 (10)
Unable to walk about 4 (2) 4 (3) 2 (2) 2 (3)
Self-care
No problems washing or dressing 96 (59) 74 (56) 67 (67) 53 (74)
Slight problems washing or dressing 32 (20) 23 (17) 12 (12) 9 (13)
Moderate problems washing or
dressing
23 (14) 23 (17) 16 (16) 5 (7)
Severe problems washing or dressing 9 (5) 8 (6) 2 (2) 4 (6)
Unable to wash or dress 4 (2) 4 (3) 3 (3) 1 (1)
Usual activities
No problems doing usual activities 20 (12) 29 (22) 30 (30) 25 (35)
Slight problems doing usual activities 41 (25) 28 (21) 15 (15) 18 (25)
Moderate problems doing usual
activities
42 (26) 33 (25) 29 (29) 16 (22)
Severe problems doing usual
activities
39 (24) 19 (14) 13 (13) 10 (14)
Unable to do usual activities 22 (13) 23 (17) 13 (13) 3 (4)
Pain/discomfort
No pain or discomfort 44 (27) 42 (32) 40 (40) 23 (32)
Slight pain or discomfort 49 (30) 49 (37) 25 (25) 30 (42)
Moderate pain or discomfort 46 (28) 34 (26) 29 (29) 14 (19)
Severe pain or discomfort 22 (13) 7 (5) 6 (6) 3 (4)
Extreme pain or discomfort 3 (2) 0 (0) 0 (0) 2 (3)
Anxiety/depression
Not anxious or depressed 68 (41) 59 (45) 47 (47) 44 (61)
Slightly anxious or depressed 48 (29) 37 (28) 34 (34) 18 (25)
Moderately anxious or depressed 37 (23) 31 (23) 14 (14) 7 (10)
Severely anxious or depressed 9 (5) 5 (4) 5 (5) 2 (3)
Extremely anxious or depressed 2 (1) 0 (0) 0 (0) 1 (1)
continued
DOI: 10.3310/hta24260 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 26
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Bhatnagar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
TABLE 34 Quality of life: EQ-5D-5L responses (continued )
EQ-5D-5L domain
Time point, n (%)
Randomisation 1 month 3 months 6 months
Thoracoscopy and talc poudrage
Mobility
No problems in walking about 34 (21) 32 (24) 27 (28) 26 (37)
Slight problems in walking about 44 (27) 40 (30) 29 (31) 23 (33)
Moderate problems in walking about 48 (29) 37 (28) 20 (21) 15 (21)
Severe problems in walking about 34 (21) 23 (17) 15 (16) 5 (7)
Unable to walk about 3 (2) 1 (1) 4 (4) 1 (1)
Self-care
No problems washing or dressing 98 (60) 85 (64) 59 (62) 48 (69)
Slight problems washing or dressing 36 (22) 26 (20) 17 (18) 18 (26)
Moderate problems washing or
dressing
22 (14) 16 (12) 12 (13) 3 (4)
Severe problems washing or dressing 6 (4) 3 (2) 4 (4) 0 (0)
Unable to wash or dress 1 (1) 3 (2) 3 (3) 1 (1)
Usual activities
No problems doing usual activities 23 (14) 26 (20) 21 (22) 23 (33)
Slight problems doing usual activities 42 (26) 38 (29) 28 (29) 20 (29)
Moderate problems doing usual
activities
47 (29) 29 (22) 18 (19) 20 (29)
Severe problems doing usual
activities
31 (19) 21 (16) 16 (17) 5 (7)
Unable to do usual activities 20 (12) 19 (14) 12 (13) 2 (3)
Pain/discomfort
No pain or discomfort 32 (20) 37 (28) 29 (30) 28 (40)
Slight pain or discomfort 64 (39) 52 (40) 33 (35) 28 (40)
Moderate pain or discomfort 46 (28) 29 (22) 25 (26) 13 (19)
Severe pain or discomfort 18 (11) 14 (11) 7 (7) 1 (1)
Extreme pain or discomfort 3 (2) 0 (0) 1 (1) 0 (0)
Anxiety/depression
Not anxious or depressed 70 (43) 58 (44) 43 (45) 36 (52)
Slightly anxious or depressed 55 (34) 48 (36) 24 (25) 20 (29)
Moderately anxious or depressed 24 (15) 18 (14) 22 (23) 11 (16)
Severely anxious or depressed 12 (7) 6 (5) 4 (4) 1 (1)
Extremely anxious or depressed 2 (1) 3 (2) 2 (2) 1 (1)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
TABLE 35 The SF-36 responses
Domain and time point
Treatment arm
p> |z|
Chest drain and slurry Thoracoscopy and poudrage
n Mean (SD) n Mean (SD)
Randomisation
Physical functioning 159 30 (25) 163 33 (29) 0.329
Role physical 163 24 (24) 164 28 (27) 0.230
Role emotional 162 53 (38) 163 54 (34) 0.761
Social functioning 163 38 (31) 162 41 (29) 0.514
Mental health 157 61 (23) 160 64 (21) 0.377
Energy/vitality 158 30 (22) 161 31 (23) 0.970
Pain 164 52 (31) 164 51 (30) 0.968
General health perception 161 40 (23) 161 41 (21) 0.501
Mental component score 142 50 (26) 148 51 (23) 0.699
Physical component score 142 26 (23) 148 27 (24) 0.556
1 month
Physical functioning 128 38 (28) 127 37 (27) 0.717
Role physical 132 30 (30) 131 32 (29) 0.503
Role emotional 131 59(35) 130 60 (36) 0.826
Social functioning 128 48 (33) 128 47 (30) 0.712
Mental health 129 65 (23) 129 65 (22) 0.910
Energy/vitality 131 34 (23) 130 34 (22) 0.886
Pain 132 60 (28) 131 55 (28) 0.167
General health perception 129 37 (21) 130 38 (20) 0.789
Mental component score 119 54 (25) 119 55 (24) 0.856
Physical component score 119 32 (25) 119 29 (26) 0.435
3 months
Physical functioning 97 44 (30) 93 40 (29) 0.335
Role physical 97 40 (34) 96 38 (29) 0.712
Role emotional 97 66 (35) 93 65 (35) 0.912
Social functioning 99 57 (33) 91 55 (31) 0.716
Mental health 98 69 (22) 91 68 (21) 0.634
Energy/vitality 99 42 (23) 93 41 (23) 0.634
Pain 99 63 (30) 94 65 (27) 0.600
General health perception 97 39 (21) 93 39 (23) 0.964
Mental component score 93 61 (24) 85 58 (25) 0.524
Physical component score 93 38 (29) 85 36 (25) 0.739
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TABLE 35 The SF-36 responses (continued )
Domain and time point
Treatment arm
p> |z|
Chest drain and slurry Thoracoscopy and poudrage
n Mean (SD) n Mean (SD)
6 months
Physical functioning 69 50 (29) 68 50 (27) 0.951
Role physical 72 48 (31) 69 49 (28) 0.830
Role emotional 72 71 (30) 69 70 (32) 0.863
Social functioning 72 60 (32) 70 65 (27) 0.263
Mental health 71 73 (21) 69 72 (20) 0.729
Energy/vitality 72 43 (25) 69 46 (23) 0.451
Pain 72 67 (29) 69 66 (28) 0.764
General health perception 72 41 (21) 69 42 (26) 0.731
Mental component score 68 62 (23) 64 64 (22) 0.650
Physical component score 68 41 (26) 64 43 (28) 0.684
TABLE 36 Resource use at each follow-up: drain insertion and talc slurry
Type of resource use
Time point, mean (SD), n
1 month 3 months 6 months
General practice consultations
Surgery 0.39 (0.65), 133 0.62 (1.17), 121 0.76 (1.48), 125
Home 0.17 (0.72), 134 0.20 (0.79), 122 0.25 (0.83), 123
Telephone 0.22 (0.69), 134 0.39 (0.99), 119 0.21 (0.71), 121
Outpatient visits 1.38 (1.52), 146 2.24 (2.43), 140 2.26 (3.01), 142
A&E visits 0.12 (0.37), 147 0.20 (0.51), 143 0.19 (0.53), 142
Ambulance use 0.06 (0.24), 144 0.12 (0.37), 138 0.09 (0.37), 138
Length of stay (days) 1.58 (3.79), 148 2.13 (5.12), 143 1.80 (4.58), 138
Hospice care
Length of stay (days) 0.01 (0.08), 139 0.10 (0.65), 133 0.99 (7.07), 130
Hospice nurse visits 0.18 (0.69), 138 0.25 (1.02), 127 0.18 (0.84), 125
Nurse consultations
Clinic 0.83 (1.27), 140 1.16 (1.87), 130 0.95 (2.10), 127
Home 0.72 (2.31), 137 3.19 (8.83), 124 3.08 (7.78), 120
Physiotherapist visits 0.10 (0.53), 139 0.06 (0.39), 125 0.06 (0.39), 124
Occupational therapist visits 0.06 (0.31), 138 0.09 (0.55), 125 0.07 (0.33), 122
Psychologist visits 0.03 (0.17), 139 0.02 (0.27), 125 0.02 (0.18), 124
Counsellor visits 0.01 (0.12), 138 0.62 (1.17), 121 0.76 (1.48), 125
Day hospital visits 0.28 (0.99), 138 0.20 (0.79), 122 0.25 (0.83), 123
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TABLE 37 Resource use at each follow-up: thoracoscopy and talc poudrage
Type of resource use
Time point, mean (SD), n
1 month 3 months 6 months
General practice consultations
Surgery 0.35 (0.61), 142 0.69 (1.03), 116 0.54 (0.99), 110
Home 0.17 (0.49), 141 0.21 (0.62), 114 0.28 (0.84), 110
Telephone 0.19 (0.56), 141 0.35 (0.80), 115 0.42 (1.17), 109
Outpatient visits 1.21 (1.45), 152 2.03 (2.28), 144 2.24 (2.99), 101
A&E visits 0.15 (0.41), 152 0.19 (0.50), 144 0.17 (0.45), 133
Ambulance use 0.08 (0.32), 152 0.06 (0.23), 141 0.08 (0.32), 131
Length of stay (days) 2.05 (4.72), 151 3.17 (7.06), 144 1.50 (3.83), 137
Hospice care
Length of stay (days) 0.13 (1.05), 145 0.55 (3.02), 132 0.78 (4.14), 121
Hospice nurse visits 0.09 (0.42), 144 0.63 (5.45), 126 0.11 (0.65), 114
Nurse consultations
Clinic 0.54 (0.93), 145 0.79 (1.38), 129 0.96 (2.10), 89
Home 0.94 (3.20), 143 2.95 (9.95), 120 3.84 (12.42), 124
Physiotherapist visits 0.04 (0.23), 146 0.09 (0.40), 127 0.17 (0.88), 121
Occupational therapist visits 0.07 (0.37), 145 0.09 (0.44), 127 0.07 (0.48), 122
Psychologist visits 0.00, 145 0.00, 130 0.07 (0.53), 118
Counsellor visits 0.02 (0.19), 144 0.02 (0.15), 127 0.07 (0.47), 118
Day hospital visits 0.29 (0.80), 146 0.62 (1.82), 131 0.44 (1.36), 119
TABLE 38 Costs (£) at each follow-up: drain insertion and talc slurry
Type of resource use
Time point, mean (SD), n
1 month 3 months 6 months
General practice consultations
Surgery 14 (23), 133 22 (42), 121 27 (53), 125
Home 16 (66), 134 18 (72), 122 23 (75), 123
Telephone 6 (19), 134 11 (28), 119 6 (20), 121
Outpatient visits 173 (190), 146 280 (303), 140 283 (377), 142
A&E visits 17 (51), 147 28 (71), 143 26 (73), 142
Ambulance use 13 (51), 144 26 (78), 138 18 (78), 138
Hospitalisations 843 (2019), 148 1166 (2801), 143 1115 (2812), 143
Hospice care
Inpatient stays 3 (34), 139 39 (259), 133 395 (2814), 130
Hospice nurse visits 20 (76), 138 28 (114), 127 20 (93), 125
Nurse consultations
Clinic 12 (18), 140 13 (26), 130 13 (29), 127
Home 29 (95), 137 131 (362), 124 126 (319), 120
Physiotherapist visits 5 (26), 139 3 (19), 125 3 (20), 124
Occupational therapist visits 4 (22), 138 6 (38), 125 5 (23), 122
Psychologist visits 4 (25), 139 4 (40), 125 2 (27), 124
Counsellor visits 2 (18), 138 6 (68), 125 8 (55), 124
Day hospital visits 208 (728), 138 600 (1662), 130 667 (2041), 128
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TABLE 39 Costs (£) at each follow-up: thoracoscopy and talc poudrage
Type of resource use
Time point, mean (SD), n
1 month 3 months 6 months
General practice consultations
Surgery 12 (22), 142 25 (37), 116 19 (36), 110
Home 15 (45), 141 19 (56), 114 26 (76), 110
Telephone 5 (16), 141 10 (22), 115 12 (33), 109
Outpatient visits 151 (181), 152 253 (285), 144 280 (374), 134
A&E visits 21 (57), 152 26 (69), 144 23 (62), 133
Ambulance use 17 (66), 152 12 (49), 141 16 (67), 131
Hospitalisations 1100 (2495), 151 1674 (4272), 144 883 (2459), 137
Hospice care
Inpatient stays 52 (418), 145 217 (1203), 132 309 (1649), 121
Hospice nurse visits 52 (418), 145 70 (605), 126 12 (73), 114
Nurse consultations
Clinic 8 (13), 145 11 (19), 129 13 (29), 124
Home 38 (131), 143 121 (408), 120 110 (431), 113
Physiotherapist visits 2 (11), 146 4 (20), 127 9 (43), 121
Occupational therapist visits 5 (25), 145 6 (30), 127 5 (33), 122
Psychologist visits 0, 145 0, 130 10 (80), 118
Counsellor visits 3 (28), 144 4 (23), 127 10 (70), 118
Day hospital visits 212 (586), 146 455 (1340), 131 321 (1003), 119
TABLE 40 Complete and missing resource-use data at the 1-month follow-up
Type of resource use
Data, n (%)
Available Missing
Alive
Dead within
follow-up
window
Dead before
follow-up Alive
Dead within
follow-up
window
Thoracoscopy and poudrage (N = 166)
General practice consultations
Surgery 134 (81) 8 (5) N/A 22 (13) 2 (1)
Home 133 (80) 5 (3) N/A 23 (14) 2 (1)
Telephone 133 (80) 8 (5) N/A 23 (14) 2 (1)
Outpatient visits 144 (87) 8 (5) N/A 12 (7) 2 (1)
A&E visits 144 (87) 8 (5) N/A 12 (7) 2 (1)
Ambulance use 144 (87) 8 (5) N/A 12 (7) 2 (1)
Hospitalisations 143 (86) 8 (5) N/A 13 (8) 2 (1)
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TABLE 40 Complete and missing resource-use data at the 1-month follow-up (continued )
Type of resource use
Data, n (%)
Available Missing
Alive
Dead within
follow-up
window
Dead before
follow-up Alive
Dead within
follow-up
window
Hospice care
Inpatient stays 138 (83) 7 (4) N/A 18 (11) 3 (2)
Hospice nurse visits 136 (82) 8 (5) N/A 20 (12) 2 (1)
Nurse consultations
Clinic 137 (83) 8 (5) N/A 19 (11) 2 (1)
Home 135 (81) 8 (5) N/A 21 (13) 2 (1)
Physiotherapist visits 138 (83) 8 (5) N/A 18 (11) 2 (1)
Occupational therapist visits 137 (83) 8 (5) N/A 19 (11) 2 (1)
Psychologist visits 137 (83) 8 (5) N/A 19 (11) 2 (1)
Counsellor visits 136 (82) 8 (5) N/A 20 (12) 2 (1)
Day hospital visits 138 (83) 8 (5) N/A 18 (11) 2 (1)
Chest drain and slurry (N = 164)
General practice consultations
Surgery 128 (78) 5 (3) N/A 22 (13) 9 (5)
Home 129 (79) 5 (3) N/A 21 (13) 9 (5)
Telephone 129 (79) 5 (3) N/A 21 (13) 9 (5)
Outpatient visits 139 (85) 7 (4) N/A 11 (7) 7 (4)
A&E visits 140 (85) 7 (4) N/A 10 (7) 7 (4)
Ambulance use 137 (84) 7 (4) N/A 13 (8) 7 (4)
Hospitalisations 141 (86) 7 (4) N/A 9 (5) 7 (4)
Hospice care
Inpatient stays 134 (82) 5 (3) N/A 16 (10) 9 (5)
Hospice nurse visits 133 (81) 5 (3) N/A 17 (10) 9 (5)
Nurse consultations
Clinic 134 (82) 6 (4) N/A 16 (10) 8 (5)
Home 131 (80) 6 (4) N/A 19 (12) 8 (5)
Physiotherapist visits 133 (81) 6 (4) N/A 17 (10) 8 (5)
Occupational therapist visits 132 (80) 6 (4) N/A 18 (11) 8 (5)
Psychologist visits 133 (81) 6 (4) N/A 17 (10) 8 (5)
Counsellor visits 132 (80) 6 (4) N/A 18 (11) 8 (5)
Day hospital visits 132 (80) 6 (4) N/A 18 (11) 8 (5)
N/A, not applicable.
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TABLE 41 Complete and missing resource-use data at the 3-month follow-up
Type of resource use
Data, n (%)
Available Missing
Alive
Dead within
follow-up
window
Dead before
follow-up Alive
Dead within
follow-up
window
Thoracoscopy and poudrage (N = 166)
General practice consultations
Surgery 98 (59) 8 (5) 10 (6) 33 (20) 17 (10)
Home 96 (58) 8 (5) 10 (6) 35 (21) 17 (10)
Telephone 98 (59) 7 (4) 10 (6) 33 (20) 18 (11)
Outpatient visits 114 (69) 20 (12) 10 (6) 17 (10) 5 (3)
A&E visits 115 (69) 19 (11) 10 (6) 16 (10) 6 (4)
Ambulance use 113 (68) 18 (11) 10 (6) 18 (11) 7 (4)
Hospitalisations 115 (69) 19 (11) 10 (6) 16 (10) 6 (4)
Hospice care
Inpatient stays 110 (67) 12 (7) 10 (6) 21 (13) 13 (8)
Hospice nurse visits 105 (63) 11 (7) 10 (6) 26 (16) 14 (8)
Nurse consultations
Clinic 105 (63) 14 (8) 10 (6) 26 (16) 11 (7)
Home 103 (62) 7 (4) 10 (6) 28 (17) 18 (11)
Physiotherapist visits 107 (65) 10 (6) 10 (6) 24 (14) 15 (9)
Occupational therapist visits 107 (65) 10 (6) 10 (6) 24 (14) 15 (9)
Psychologist visits 109 (66) 11 (7) 10 (6) 22 (13) 14 (8)
Counsellor visits 107 (65) 10 (6) 10 (6) 24 (14) 15 (9)
Day hospital visits 108 (65) 13 (8) 10 (6) 23 (14) 12 (8)
Chest drain and slurry (N = 164)
General practice consultations
Surgery 99 (60) 8 (5) 14 (9) 23 (14) 20 (12)
Home 99 (60) 9 (5) 14 (9) 23 (14) 19 (12)
Telephone 98 (60) 7 (4) 14 (9) 24 (15) 21 (13)
Outpatient visits 104 (63) 22 (14) 14 (9) 18 (11) 6 (4)
A&E visits 107 (66) 22 (14) 14 (9) 15 (9) 6 (4)
Ambulance use 106 (65) 18 (11) 14 (9) 16 (10) 10 (6)
Hospitalisations 107 (66) 22 (14) 14 (9) 15 (9) 6 (4)
Hospice care
Inpatient stays 106 (65) 13 (8) 14 (9) 16 (10) 15 (9)
Hospice nurse visits 103 (63) 10 (6) 14 (9) 19 (12) 18 (11)
Nurse consultations
Clinic 100 (61) 16 (10) 14 (9) 22 (13) 12 (7)
Home 100 (61) 10 (6) 14 (9) 22 (13) 18 (11)
Physiotherapist visits 100 (61) 11 (7) 14 (9) 22 (13) 17 (10)
Occupational therapist visits 100 (61) 11 (7) 14 (9) 22 (13) 17 (10)
Psychologist visits 100 (61) 11 (7) 14 (9) 22 (13) 17 (10)
Counsellor visits 100 (61) 11 (7) 14 (9) 22 (13) 17 (10)
Day hospital visits 102 (62) 14 (9) 14 (9) 20 (12) 14 (9)
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TABLE 42 Complete and missing resource-use data at the 6-month follow-up
Type of resource use
Data, n (%)
Available Missing
Alive
Dead within
follow-up
window
Dead before
follow-up Alive
Dead within
follow-up
window
Thoracoscopy and poudrage (N = 166)
General practice consultations
Surgery 70 (42) 5 (3) 35 (21) 32 (19) 24 (14)
Home 70 (42) 5 (3) 35 (21) 32 (19) 24 (14)
Telephone 69 (42) 5 (3) 35 (21) 33 (20) 24 (14)
Outpatient visits 79 (48) 20 (12) 35 (21) 23 (14) 9 (5)
A&E visits 78 (47) 20 (12) 35 (21) 24 (14) 9 (5)
Ambulance use 77 (46) 19 (11) 35 (21) 25 (15) 10 (6)
Hospitalisations 81 (49) 21 (13) 35 (21) 21 (13) 8 (5)
Hospice care
Inpatient stays 75 (45) 11 (7) 35 (21) 27 (16) 18 (11)
Hospice nurse visits 72 (43) 7 (4) 35 (21) 30 (18) 22 (13)
Nurse consultations
Clinic 76 (46) 13 (8) 35 (21) 26 (16) 16 (10)
Home 73 (44) 5 (3) 35 (21) 29 (17) 24 (14)
Physiotherapist visits 74 (45) 12 (7) 35 (21) 28 (17) 17 (10)
Occupational therapist visits 75 (45) 12 (7) 35 (21) 27 (16) 17 (10)
Psychologist visits 74 (45) 9 (5) 35 (21) 28 (17) 20 (12)
Counsellor visits 74 (45) 9 (5) 35 (21) 28 (17) 20 (12)
Day hospital visits 74 (45) 10 (6) 35 (21) 28 (17) 19 (11)
Chest drain and slurry (N = 164)
General practice consultations
Surgery 75 (46) 8 (5) 42 (26) 23 (14) 16 (10)
Home 75 (46) 6 (4) 42 (26) 23 (14) 18 (11)
Telephone 74 (45) 5 (3) 42 (26) 24 (15) 19 (12)
Outpatient visits 82 (50) 18 (11) 42 (26) 16 (10) 6 (4)
A&E visits 81 (49) 19 (12) 42 (26) 17 (10) 5 (3)
Ambulance use 81 (49) 15 (9) 42 (26) 17 (10) 9 (5)
Hospitalisations 82 (50) 19 (12) 42 (26) 16 (10) 5 (3)
Hospice care
Inpatient stays 78 (48) 10 (6) 42 (26) 20 (12) 14 (9)
Hospice nurse visits 76 (46) 7 (4) 42 (26) 22 (13) 17 (10)
Nurse consultations
Clinic 76 (46) 9 (5) 42 (26) 22 (13) 15 (9)
Home 74 (45) 4 (2) 42 (26) 24 (15) 20 (12)
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TABLE 42 Complete and missing resource-use data at the 6-month follow-up (continued )
Type of resource use
Data, n (%)
Available Missing
Alive
Dead within
follow-up
window
Dead before
follow-up Alive
Dead within
follow-up
window
Physiotherapist visits 74 (54) 8 (5) 42 (26) 24 (15) 16 (10)
Occupational therapist visits 73 (45) 7 (4) 42 (26) 25 (15) 17 (10)
Psychologist visits 75 (46) 7 (4) 42 (26) 23 (14) 17 (10)
Counsellor visits 75 (46) 7 (4) 42 (26) 23 (14) 17 (10)
Day hospital visits 78 (48) 8 (5) 42 (26) 20 (12) 16 (10)
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Appendix 3 The TAPPS trial patient
information sheet
TAPPS TRIAL
1. Invitation
2. Trial description
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3. What is the purpose of the trial?
There have been previous studies which have attempted to identify which of these 
two methods is the best way to apply talc, but none so far have been able to provide
doctors and patients with a complete answer. This study therefore looks to 
deinitively establish which method of applying talc, slurry or poudrage, is the most
effective at preventing luid recurrence for patients, and the most cost-effective for 
healthcare providers such as the NHS. We shall also be collecting information on
patients’ symptoms and quality of life during the trial to see if one treatment is
better than the other from the patient point of view. 
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5. Do I have to take part? 
6. If I agree to participate, will I deinitely have one of the 
procedures, and will I deinitely receive talc? 
7. I am currently receiving chemotherapy/radiotherapy for my
cancer. Will being in the trial affect my other treatments? 
4. Why have I been chosen? 
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9. What will happen to me at the beginning of the trial?
a. Chest drain and slurry. 
8. If I take part in the trial, what will happen to me before I enter 
the trial?
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10. What will happen to me once I’ve left hospital?
b. Thoracoscopy and poudrage. 
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11. Information about talc
12. Information about chest drains
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14. What are the potential beneits from taking part? 
15. What are the possible disadvantages and risks of taking
part? 
13. Information about thoracoscopy 
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17. Stopping your participation in the trial 
16. Will my medical information be kept conidential? 
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19. What if there is a problem? 
20. Who is organising and funding the research?
21. Who has reviewed and approved the trial?
18. What if new information becomes available?
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23. What will happen to the samples taken in the trial?
24. Will any genetic tests be performed?
22. What will happen to the results of the trial?
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26. What happens if I decide not to participate?
Thank you for taking the time to read this information, and for 
considering taking part in the TAPPS trial.
25. What do I need to do now if I agree to participate?
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